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Mutations in the lysosome membrane protein Niemann-Pick C1 (NPC1) 
are known to cause a generalized block in retrograde vesicle-mediated transport 
from the lysosome, resulting in the hyper-accumulation of multiple lysosomal 
cargos.  As a result, the true substrate of NPC1 is controversial and not fully 
understood at the current time.  An important, yet often overlooked, category of 
lysosomal cargo includes the vast array of small molecular weight amine-
containing molecules that are substrates for ion trapping in the highly acidic 
organelle lumen.  In this dissertation, we provide experimental evidence to 
support a novel functional role for NPC1 involving the intracellular trafficking of 
amine-containing molecules. 
 
In the present study, we show for the first time that lysosomal 
accumulation of weakly basic amine-containing molecules can significantly 
stimulate fusion of lysosomes with late endosomes.  Subsequently, we observe 
significant enhancements in the trafficking of lysosomal cargo to the cell 
periphery.  These effects are not observed in NPC1 deficient cells suggesting 
that NPC1 responds to lysosomal amine build-up and regulates lumenal 
 iii 
concentrations by facilitating their removal.  Furthermore, using methods 
developed to quantitatively evaluate lysosome secretion and late endosome-
lysosome fusion, we have identified a number of amine-containing molecules that 
either stimulate or inhibit NPC1 function.  To illustrate the physiological 
importance of this NPC1-mediated transport pathway we evaluated the toxic 
effects of an endogenous toxic polyamine metabolite 3-aminopropanal (3-AP).  
We demonstrate that NPC1-deficient cells are more susceptible to the toxic 
effects of this metabolite, such as lysosome rupture, due to inefficient efflux of 
lysosome contents.  Moreover, Niemann-Pick Type C (NP-C) fibroblasts are 
shown to have higher levels and activities of polyamine regulating enzymes 
including polyamine oxidase, an enzyme involved in the formation of 3-AP.  
Collectively, these findings provide strong support for a novel functional role for 
NPC1 and may also provide clues towards understanding NP-C disease 
progression. 
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1.1. Introduction 
Research on Niemann-Pick Type C (NP-C) disease has been ongoing for 
several decades.  Although much research has been performed over this time, a 
function for the protein responsible for the disease, Niemann-Pick C1 (NPC1), 
remains elusive.   
This introductory chapter provides a review of relevant areas concerning 
our proposed novel cellular function for the NPC1 protein.  First, there will be an 
introduction to the lysosome compartment and its relevant cellular functions.  
There will be discussion on the known mechanisms for molecules to enter 
lysosomes as well as known mechanisms for efflux of lysosome contents.  The 
second section will include a brief introduction to NP-C disease and NPC1.  This 
section will highlight relevant research and conclusions to date.  In conclusion, 
there will be a review on physiologically relevant amine containing molecules and 
how they could play a role in neurodegenerative diseases like NP-C disease.  
Specifically, there will be a discussion about endogenous polyamines and their 
metabolites.   
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1.2. The lysosome 
1.2.1. Overview of the lysosome 
 Lysosomes were originally discovered in 1949 by Christian de Duve upon 
the observation of acid-phosphatase activity in sub-cellular fractions of liver [1].  
Lysosomes are now known to be an integral part of the endocytic pathway in 
cells.  By definition, lysosomes are membrane bound organelles that possess an 
array of active acid hydrolase enzymes and a low lumenal pH (typically pH 4-5) 
which is approximately 2 units below the surrounding cytoplasm  [2].  Their 
membranes are typically laden with glycoproteins (i.e. lysosome associated 
membrane protein, LAMP and lysosome glycoprotein, LGP) and phospholipids 
(lysobisphosphatidic acid, LBPA) not found at high concentrations in other 
locations in the cells except for late endocytic compartments [3; 4].  Lysosomes 
are further defined and distinguished from endosomes in the endocytic pathway 
by the absence of mannose-6-phosphate receptors (MPR, late endosomes) and 
plasma membrane recycling receptors like the transferrin receptor (early 
endosomes) [5; 6; 7].  Their morphology in cells has been shown to be 
heterogeneous and electron dense when observed by electron microscopy (EM) 
[8].  Furthermore, using EM, the inner core of lysosomes has been shown to be 
multi-vesicular, indicating that more than one membranous structure is present 
within the organelle and heterogenous with respect to internal osmolarity [8; 9].  
Lysosomes have been shown to contribute approximately 6 pL to total cellular 
volume, which has been proposed to be 0.5-5% of the total depending on cell-
type [8; 10; 11].   
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Since de Duve’s discovery, lysosomes have been well-studied and 
generally regarded as a terminal static degradative compartment within the 
endocytic pathway [12].  This notion has been challenged by several recent lines 
of evidence: 1) that lysosomes can interact with other organelles in the endocytic 
pathway, specifically late endosomes [13; 14] and 2) the discovery that similar to 
secretory lysosomes, conventional lysosomes can be stimulated to fuse directly 
with the plasma membrane [15].  These findings are discussed in detail below.   
 
1.2.2. Lysosome dynamics 
 To put lysosomes into context with other organelles in the endocytic 
pathway, a general schematic of how macromolecules can localize within 
lysosomes is shown in Figure 1.1.  As seen in Figure 1.1, the pathway for 
endocytic delivery into lysosomes occurs after endocytosed materials pass 
through early endosomes and late endosomes.  The final step is thought to occur 
through some type of interaction with late endosomes, although there is much 
debate on how this is accomplished.  The traditional maturation model for 
endocytic delivery to lysosomes proposes that early endosomes mature into late 
endosomes which subsequently mature into lysosomes with the resulting 
organelle phospholipid bilayer being composed of initial plasma membrane [4; 7; 
12; 16].  This is unlikely, however, since components common to the plasma 
membrane are not found in early and late endosomes and that these organelles 
are biochemically unique [17].  The maturation of late endosomes to lysosomes  
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has not been fully discounted and may contribute to lysosome localization of 
macromolecules to some degree [8; 18; 19].  A more recent maturation model 
suggests lysosome biogenesis occurs as a result of continuous organelle-mediated 
interactions that add and remove components from endosomes to ultimately form 
the lysosome [16].  For example, late endosomes and their contents can become 
lysosomes by removal of membrane proteins (such as MPR), further lowering of pH, 
and increases in density [4; 20].  On the other hand, it has been suggested that cells 
possess an initial amount of lysosomes following cell division which are maintained 
and reformed from these types of interactions.  Recent mechanisms that address 
these possibilities include the “kiss and run” and hybrid organelle models (see Figure 
1.2) [21; 22; 23].  
 
 An essay by Storrie and Desjardins proposed a “kiss and run” theory for 
macromolecule delivery to lysosomes in response to observations of fluorescence-
labeled endosomes transiently bumping into each other and separating [21].  
Elegant investigations by Bright et al. using EM and fluorescence microscopy 
confirmed that this mechanism occurs readily in living cells by observing, in real-
time, differentially labeled late endosomes physically making contact with 
lysosomes, docking, depositing their contents, and then separating [24].  
Furthermore, these investigations revealed that complete organelle fusion events (or 
hybrid organelle formation) between late endosomes  
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and lysosomes also occur readily in living cells.  It was reported by Bright et al. 
that these two mechanisms (kiss and run, hybrid organelle formation) accounted 
for all content transfer between late endosomes and lysosomes [24].   
 
In 1989, Mullock et al. reported the use of a cell-free assay for 
investigating the ability of late endosomes to fuse with lysosomes forming a 
hybrid organelle of intermediate properties [25].  Hybrid organelle formation 
events were shown in vitro through the mixing of reconstituted fractions of late 
endosome and lysosomes.  Heterotypic fusion events between late endosomes 
and lysosomes were found to be dependent on the presence of ATP, cytosol, 
calcium, and temperature [13; 26].  The use of such an assay has shown that all 
membrane fusion events occurring between late endosomes and lysosomes are 
doing so with general cytosolic fusion machinery, which requires NSF (N-
ethylmaleimide sensitive factor) and SNAPs (soluble NSF attachment proteins) 
functioning by the SNARE (SNAP receptor) mechanism [27; 28].  According to 
Rothman and Warren, the SNARE hypothesis (originally discussed by Rothman 
in 1993 [29]) provides a mechanism for the specific docking and fusion of 
transport vesicles with their target membrane (in this case late endosomes with 
lysosomes or vice versa) [30].  This is accomplished through the pairing of 
specific vesicle (v) and organelle target (t) SNAREs that form a trans-SNARE 
complex which pull the organelles intimately together [8; 30].  In addition to these 
components, Mullock et al. further demonstrated that a small GTPase from the 
Rab family is involved by inhibiting late endosome-lysosome fusion with a Rab 
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GDP dissociation inhibitor, which maintains the Rab’s inactive form [28; 31].  
Rabs are organelle specific proteins that are believed to function in the 
recognition of target membranes as tethers which specifically link organelles 
together before trans-SNARE formation [32; 33].  
 
Luzio et al. proposes that hybrid organelle formation by fusion of late 
endosomes and lysosomes follows the traditional steps for membrane fusion: 1) 
tethering by NSF, SNAP, and Rab proteins, where the two organelles form links 
with each other, 2) the formation of the trans-SNARE complex between v- and t-
SNARES, and 3) membrane fusion [8].  The formation of the intermediate trans-
SNARE complex has been shown to be necessary but not sufficient for 
membrane fusion upon discovery that calcium and calmodulin are required for 
the late steps of membrane fusion [26; 34].  In addition, optimal lipid composition 
and asymmetry (curvature) of the phospholipid bilayer are important for 
successful membrane fusion [35].  The presence of lipid-rich domains such as 
sphingomyelin and cholesterol in membranes has been shown to favor organelle 
fusion [36; 37].  In particular, cholesterol facilitates high negative spontaneous 
curvature of lipid bilayers that has been shown experimentally to drive fusion 
events in liposomes [35; 38].  Furthermore, it was demonstrated that cholesterol 
supports the formation and transition of transient fusion intermediates like the 
trans-SNARE complex [35].   
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 Conventional lysosomes have been shown to fuse with the plasma 
membrane upon stimulation with high concentrations of cytosolic calcium [15; 39; 
40].   The purpose for such events have been demonstrated when cells are 
injured and are in need of repair since fusion with lysosomes provides 
immediately available phospholipid membranes for resealing [41; 42].  Similar to 
fusion with late endosomes, lysosome fusion with the plasma membrane requires 
the same fusion machinery (tethers, trans-SNARE formation, etc.) [43].  
However, the process is regulated by two key components: cytosolic calcium 
concentrations and synaptotagmin-VII, a calcium sensor that localizes to 
lysosomes [44; 45].  Cytosolic Ca2+ concentrations of approximately 1-5 µM have 
been shown to stimulate lysosome fusion with the plasma membrane, which 
according to Pryor et al., is almost 15-fold higher than what is required for late 
endosome-lysosome fusion [26].  There also exist specialized secretory 
lysosomes, such as mast-cell secretory granules, basophil granules, and many 
others that co-exist with conventional lysosomes in certain cell types [46; 47].  
Similar to conventional lysosomes, these secretory compartments can be 
stimulated to fuse with the plasma membrane to release their respective cargos 
[46].  A more in-depth discussion concerning secretory lysosomes has been 
omitted here since this review is focused on the dynamics of conventional 
lysosomes. 
 
The two examples described here, late endosome-lysosome and 
lysosome-plasma membrane fusion, highlight the emerging identity of the 
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dynamic lysosome.  As described, the lysosome is unlikely to be considered a 
static or terminal compartment as was previously thought. 
 
1.2.3. Delivery of materials out of the lysosome 
 The previous section discussed the dynamic trafficking events which result 
in the localization of endocytosed macromolecules to the lysosome.  In this 
section, I will discuss how the formation of a hybrid organelle compartment can 
allow trapped molecules to escape from the lysosomal lumen to the extracellular 
space.   
 
 As described above, hybrid organelle formation results from the fusion of 
late endosomes and lysosomes.  It seems intuitive that if late endosomes and 
lysosomes were to engage in several of these fusion events without being 
reformed they would essentially be “used up”.  Thus, there must be a mechanism 
for the reformation of these compartments after hybrid organelle formation.  
Furthermore, this mechanism must take into account the following requirements: 
1) lysosomes are much denser than hybrid organelles, so there must be 
condensing of lumenal components and 2) organelle specific membrane proteins 
must be segregated.  To support the first requirement, there is evidence 
suggesting that regulated secretory vesicles in neuroendocrine cells undergo 
condensation by the removal of non-secretory components through the budding 
of small vesicles from maturing granules [48].  This process was found to be 
dependent on the low lumenal pH of the granule and calcium concentrations.  
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Similar to this mechanism, Bright et al. used electron microscopy to show that 
lysosomes can be reformed from hybrid organelles [49].  To describe this, cells 
were first labeled with 10 nm BSA-gold particles which were allowed to localize to 
lysosomes.  Next, 15 nm BSA-gold particles were endocytosed and allowed to 
localize to late endosomes.  Initially, the 10 nm BSA-gold particles were in MPR 
negative lysosomes and the second pulse of 15 nm BSA-gold was in MPR-
positive late endosomes.  After time, it was observed that lysosomes had both 
sizes of BSA-gold in their lumen suggesting that lysosomes interacted with late 
endosomes and were re-usable since they received two different pulses of BSA-
gold.  In another attempt to describe this mechanism, Pryor et al. used the 
previously described in vitro assay for assessing hybrid organelle formation to 
describe lysosome reformation by observing organelle density changes by 
ultracentrifugation on Nycodenz gradients [26].  At various times post-hybrid 
organelle formation, they observed the movement of lysosomes to different 
fractions by monitoring N-acetyl-β-glucosaminidase activity, a lysosomal enzyme.  
Over time, as lysosomes reformed, they became denser and were able to 
separate from the less dense late endosomes and remaining hybrid organelles.  
Interestingly, similar to the neuroendocrine granules described above, this 
process was inhibited by raising the lumenal pH using bafilomycin A1 or 
removing calcium using the chelator EGTA [26].   
 
The next obvious consideration for lysosome reformation is the 
segregation of membrane or membrane-associated proteins from the hybrid 
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organelle, with the most obvious candidate being MPR, since lysosomes are 
defined as MPR-negative organelles (see above) [7].  The MPR recycling 
pathway from late endosomes to the Golgi apparatus has been well-described by 
others [5; 32; 50].  The removal of MPR from hybrid organelles and subsequent 
recycling to the Golgi apparatus has been shown to occur via coated vesicles 
which at present have unknown lumenal cargo(s) [51].  Retrograde traffic from 
hybrid organelle to Golgi has been proposed to be a major mechanism for the 
exocytosis of unwanted lysosome contents since the Golgi is known to secrete 
continuously to the plasma membrane and conventional lysosomes do not unless 
stimulated with high calcium concentrations [18; 52].  As mentioned above, 
however, there is little information to date about the fluid phase cargo that 
transport vesicles from hybrid organelles to Golgi would contain [51].  It is 
unlikely that lysosome enzymes, like cathepsin-B, are the primary cargo since 
the presence of active forms of these enzymes are not present at the cell 
periphery to a significant degree [53].  Considering this, it seems these vesicles 
provide a plausible vector for the removal or recycling of non-resident materials 
and the repackaging of lysosome enzymes.   
 
1.2.4. Lysosome storage disorders 
 There is no doubt that lysosomes function in the cell to break down 
endocytosed materials, as well as endogenous components targeted for 
recycling (i.e. proteins and membranes).  Genetic impairment in normal lysosome 
function (i.e. enzyme metabolism or transport) results in lysosomal storage 
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disorders, which are characterized by the build-up of a substrate or metabolite in 
the lysosome lumen.  To date there have been many different lysosome storage 
disorders described in the literature.  Typically, these storage disorders are 
classified into subgroups according to their biochemical deficiency.  For example, 
if lysosomes have dysfunctional sphingomyelinase activity which results in the 
build-up of sphingomyelin then the disorder is considered a sphingolipidosis.  
Typically, lysosome storage disorders affect lysosome rich areas of the body 
such as the spleen or liver, or areas that are rich in lysosomal substrate.  For 
example, as a consequence of being rich in gangliosides, the brain is more 
affected by gangliosidosis than other areas.  The two best examples of this are 
Tay-Sach’s and Sandhoff’s disease which are characterized by the build-up of 
GM2 gangliosides due to defects in lysosomal hexosaminidase A and/or B 
activity, respectively [54; 55].  Both of these disorders result in severe neurologic 
impairment and death.  
 
 Along with the classification of lysosome storage disorders into subgroups, 
further classification of these groups can be made by identifying the dysfunctional 
protein as soluble or insoluble.  Soluble protein disorders typically result from 
deficiencies in enzyme activity as described above for Tay Sach’s and Sandhoff’s 
disease.  There are cases where disorders result from dysfunctional soluble 
proteins that are not enzymes, as is the case for Niemann-Pick C2, which has 
been shown to insert and remove cholesterol from lipid bilayers [56; 57].  
Furthermore, soluble protein disorders can be treated with greater success using 
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enzyme replacement or substrate reduction therapies, except for neurological 
disorders due to complications with delivery across the blood brain barrier [58; 
59].  Insoluble protein disorders result from malfunctioning lysosome membrane 
proteins.  Unlike soluble protein disorders, insoluble proteins typically function in 
the transport of a substrate from the lumen to other parts of the cell.  The two 
best examples are mucolipidosis type IV (MLIV) and Niemann-Pick Type C (NP-
C) disease.  Mucolipin-1, the lysosome membrane protein defective in MLIV, has 
been shown to be involved in the sub-cellular transport of sphingolipids, 
phospholipids, and acid mucopolysaccharides [60].  Similar to MLIV, NP-C 
disease is characterized by the build-up of cholesterol, sphingolipids, 
phospholipids and gangliosides [61].   
 
 Interestingly, there are many lysosome storage disorders that are 
inefficient at secreting lysosome contents to the cell periphery.  Chediak-Higashi, 
Griscelli and Hermansky-Pudlak syndromes all result from defects in normal 
secretion of lysosomal contents [46; 62; 63].  In addition, NP-C disease has been 
shown to have inefficient egress of lysosome contents [64; 65].  This disease and 
the protein responsible, Niemann-Pick C1, are discussed in greater detail in the 
next section. 
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1.3. Niemann-Pick Type C disease and the Niemann-Pick C1 protein 
1.3.1. Niemann-Pick Type C disease 
 Niemann-Pick Type C (NP-C) disease is an extremely rare childhood 
disorder that results in severe neurodegeneration, hepatosplenomegaly, and 
ultimately death [66; 67].  Unlike Niemann-Pick Types A and B, which result from 
deficient sphingomyelinase activity [68], NP-C is hallmarked by a 
hyperaccumulation of free unesterified low-density lipoprotein (LDL) derived 
cholesterol in lysosomes and late endosomes of affected cells.  This 
hypreaccumulation phenotype can be visualized by staining cellular cholesterol 
with the polyene antibiotic filipin (Fig. 1.3) [67; 69; 70].    The inability of affected 
cells to efficiently transfer unesterified cholesterol from endosomes/lysosomes 
results in the inability to down-regulate key components of endogenous 
cholesterol synthesis and uptake.  These components include 3-hydroxy-3-
methyl-glutaryl coenzyme A (HMG-CoA) reductase (a key enzyme necessary for 
endogenous cholesterol synthesis), and the LDL-receptor (necessary for the 
endocytosis of cholesterol-laden LDL particles) [71].  Thus, NP-C disease is 
classified as a lysosomal storage disorder and the uptake of LDL-derived 
cholesterol in affected cells remains continuous [72].  
 
NP-C disease is autosomal recessive and is caused by mutations in the npc1 
gene, which results in a mutated non-functional form of the encoded protein 
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 Niemann-Pick C1 (NPC1) [73].  At the time of this thesis, there have been over 
200 different reports of NP-C disease causing mutations [74].  In 2004, further 
analysis revealed that 23% are non-sense mutations which result in a truncated 
form of NPC1.  The other 77% of these mutations are point mutations and result 
in amino acid substitutions [75].  These substitutions are found in all areas of the 
protein and have no significant trend with regards to amino acids, (i.e. 
hydrophobic residue for a charged residue) or location (i.e. lumenal vs. 
transmembrane) [75]. 
 
 The neurodegeneration prevalent in NP-C disease has been shown to 
manifest itself in the form of impaired motor movement and tremors.  In some 
cases, heterozygous NP-C carriers experience these symptoms later in life [76].  
To this end, researchers have identified that neurodegeneration occurs primarily 
in the cerebellum by observations of increased Purkinje cell death [77; 78; 79; 
80].  The cerebellum is an area of the brain that contributes heavily to sensory 
perception, coordination and motor function which correlates with disease 
pathology.  Apart from these observations, significant loss of neurons in other loci 
of the brain has not been reported, although there is generalized atrophy of the 
central nervous system.     
 
1.3.2. Niemann-Pick C1 protein 
NPC1 is a large transmembrane protein that resides on the membranes of 
lysosomes and late endosomes.  The protein comprises of 1278 amino acids and 
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has a predicted molecular weight of 142 kDa, though the protein is glycosylated 
resulting in increased mass [73; 81].  The protein consists of 13 transmembrane 
domains, 3 large lumenal loops, multiple cytosolic loops and a cytosolic C-
terminal tail (see Figure 1.4 for protein topology) [75; 82].  The C-terminal tail 
possesses a lysosome targeting sequence in the form a dileucine motif [83], 
which has been shown to target other membrane proteins to the lysosome [84].  
This sequence is not needed for targeting membrane proteins to late 
endosomes, which suggests the protein resides in lysosomes more than late 
endosomes, although both localizations have been observed to varying degrees 
[85].   
 
1.3.3. Function of Niemann-Pick C1 
Structural comparisons between NPC1 and other proteins have been 
performed in an attempt to discover NPC1 function (i.e. structure implying 
function).  A particular transmembrane amino acid sequence was shown to have 
similarity with the sterol sensing regions of the morphogen receptor PATCHED, 
SREBP cleavage-activating protein (SCAP) and HMG-CoA reductase proteins 
[75; 82; 86; 87].  These proteins are necessary for cholesterol homeostasis and 
all have putative sterol sensing domains which were identified by Carstea et al. 
for NPC1 [73; 88].  These findings suggest that NPC1 plays an important role in 
trafficking lysosome cholesterol.  A unique lipoprotein-attachment site, similar to 
that found in prokaryotic transmembrane proteins, is found multiple times in 
NPC1’s protein sequence [89].  These sites have been shown to be prevalent in 
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the resistance-nodulation-division (RND) family of prokaryotic permeases [90].  
Further research revealed that NPC1 and members of the RND family share the 
same RND signature repeated twice: six transmembrane domains separated by 
a large hydrophilic loop [89].  RND-permeases have been shown to transport a 
variety of cargos which include lipophilic drugs and fatty acids [91; 92].  These 
results suggest that NPC1 is functioning as a membrane transporter of 
cholesterol. 
 
Traditionally, NPC1 has been implicated as a cholesterol transporter due 
to the cholesterol hyperaccumulation phenotype associated with NP-C disease 
and the presence of structural elements associated with cholesterol trafficking 
(see above).  However, functional studies with regards to NPC1 transporting 
cholesterol have been disappointing.  In NPC1-expressing E. coli, NPC1 was 
shown to transport fatty acids, but not cholesterol or cholesterol esters [89].  If 
cholesterol was indeed NPC1’s primary substrate, then binding of cholesterol to 
NPC1 should occur with great affinity.  To test this, investigators used a 
photoactivatible crosslinker attached to cholesterol (azo-cholesterol) and showed 
that NPC1 could bind low levels of cholesterol in cell culture models [93].  Most 
recently, Infante et al. reported that purified NPC1 could bind both cholesterol 
and oxysterols, with oxysterols such as 25-hydroxycholesterol having much 
higher affinity for NPC1 [94].  This supports previous observations using azo-
deriviatives of cholesterol that showed NPC1 binds cholesterol with low affinity 
and suggests that LDL-derived cholesterol is not NPC1’s primary substrate.     
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There is no question that malfunctioning NPC1 negatively affects 
cholesterol traffic from lysosomes; however, is this due to NPC1’s true functional 
role?  Interestingly, investigations have revealed that cholesterol is not the only 
molecule that hyperaccumulates in NP-C diseases lysosomes.  Gangliosides, 
sphingoid bases, phospholipids, and glycolipids have all been shown to 
accumulate in lysosomes of NP-C cells [65; 95].  Thus, the possibility exists that 
NPC1 may not function solely as a cholesterol transporter but may play a more 
general role in the egress of lysosome contents resulting in indirect cholesterol 
accumulation.  In support of this, we and others have observed that a 
generalized block in secretion of lysosome contents occurs in NP-C disease cells 
[64; 65].  In our lab, we showed that multi-drug resistant HL-60 cancer cells with 
a dysfunctional form of NPC1 were able to sequester weak bases without 
subsequent egress to the plasma membrane, unlike normal cells [64].  Studies 
by Neufeld et al. demonstrated that fluid phase endocytosis markers, such as 
sucrose, could be localized to NPC1 containing lysosomes but were inefficiently 
trafficked elsewhere in NP-C cells [65].  Furthermore, NP-C cells have an inability 
to correctly sort MPR, suggesting transport between late endosomes and the 
Golgi apparatus is defective [65].  Accordingly, the true functional role of the 
NPC1 protein remains controversial and is, perhaps, best described as unknown. 
 
1.3.4. Therapies for NP-C disease 
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 As discussed above, the function of NPC1 is unclear at present.  Thus, 
therapeutic endeavors aimed at increasing the lifespan of affected individuals or 
delaying onset of disease have been met with limited success.       
      
The notion of NPC1 as a cholesterol transporter has dominated 
therapeutic research for many years.  The early work of Pentchev and others 
showed that NPC-diseased cells were laden with LDL-derived free unesterified 
cholesterol, which was thought to be the direct cause of NP-C disease pathology 
[67].  To address this possibility, researchers examined the effects of reducing 
cholesterol build-up in lysosomes on longevity and disease progression.  To 
accomplish this, three approaches have been taken: 1) dietary limitations on 
cholesterol, 2) cholesterol lowering drugs, 3) genetic manipulation of cholesterol 
uptake.  First, feline models of NP-C disease were observed with or without 
cholesterol in their daily diet.  The onset of disease progression, as determined 
by appearance of tremors, dysmetria, and atrophy, did not change with 
restrictions in dietary cholesterol [96].  Second, the lowering of cholesterol levels 
in NP-C murine models was accomplished through the use of pharmacological 
agents, such as the cholesterol lowering drug probucol.  Administration to NP-C 
mice resulted in a significant decrease in liver cholesterol levels (up to ~50%) 
when compared to control NP-C mice [97].  However, the onset of ataxia and 
tremor was not statistically significant with untreated NP-C mice.  In the same 
study, genetic manipulations were performed to address the source of 
cholesterol build-up in lysosomes of NP-C mice, the LDL-receptor.  Double 
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knockout mice were bred that had deficiencies in both NPC1 protein and LDL-
receptor.  Interestingly, cholesterol levels were similar in LDL-receptor negative 
NP-C mice and showed the same disease progression time-line as the single 
knockout NP-C murine model [97].     
It is becoming increasingly apparent that in order to effectively treat NP-C 
disease there must be a functional understanding of NPC1 in the cell.  The 
treatments described above are meant to alleviate disease phenotypes but are 
lacking with regards to rationally developing a strategy to address NPC1 
dysfunction.  In the next sections there will be a discussion concerning other 
molecules, besides lipids, that may contribute to NP-C disease pathology.  In 
particular, the accumulation of weakly basic amines will be examined.   
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1.4. Significance of lysosomal amine sequestration and NP-C disease 
1.4.1. Overview of pH-partitioning 
 Typically, there are two ways that weakly basic amines can localize within 
the lysosome lumen to a significant degree: 1) passive-diffusion and 2) fluid 
phase endocytosis as described above in Section 1.2.  This section will 
concentrate on passive diffusion mechanisms for weakly basic amine 
accumulation in lysosomes.  Of the indicated pathways, this mechanism has the 
highest sequestration capacity if conditions associated with the cell and the 
amine are optimal, as will be discussed.  Endocytosis is a very dynamic process; 
however, its ability to concentrate amines into lysosomes is minimal when 
compared to passive mechanisms. 
  
 Most researchers agree that the accumulation of amines in lysosomes 
occurs by a passive pH-partitioning mechanism [10; 98; 99; 100; 101].  A basic 
overview of this process is depicted in Figure 1.5; however, for a more in-depth 
quantitative perspective Christian de Duve, the discoverer of lysosomes, has 
reviewed weak base sequestration in detail [102].  Briefly, a weak base in its 
unionized and membrane permeable form (B, Fig. 1.5) can diffuse through the 
lysosome membrane after traversing the plasma membrane and cytosol.  The 
cytosol has been shown to have a pH around neutrality and thus weak bases that 
have pKa values near this will exist to a significant degree in the free base form. 
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Once inside the acidic lysosome lumen, weak bases experience a shift in 
ionization equilibrium to favor the protonated form (BH+) and will sequester here 
due to the inability of the base in its charged form to permeate back across the 
membrane.  It is important to note that the charged species must not be 
membrane permeable in order for sequestration, otherwise accumulation will not 
occur [103].  In addition, the low pH of the lysosome must be maintained in order 
for significant accumulation of weak bases to occur [101; 104].  If these 
requirements are met, at steady state there will be a dramatically increased 
concentration of weak bases in lysosomes as compared to the cytoplasm.  The 
pKa value of the weak base has been correlated with the capacity for 
sequestration, in which higher values result in higher lumenal concentrations 
[105].  Evaluations with weakly basic vital stains such as neutral red provided 
some of the first evidence supporting the extreme concentrative capacity of 
lysosomes for basic molecules [106].  
 
1.4.2. Endogenous molecules that substrates for pH-partitioning 
 Cells are known to be continuously exposed to high concentrations of 
endogenous biogenic amines, polyamines, and their metabolites [107; 108].  
Despite the fact that these molecules are not fluorescent, making it difficult to 
analyze their intracellular localization, a number of reports have suggested that 
these molecules and their metabolites can become extensively 
compartmentalized in lysosomes [109; 110; 111].  
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 The polyamines; spermine, spermidine, and their di-amine precursor 
putrescine, are positively charged aliphatic amines that have been shown to be 
essential for the normal growth of cells.  Using polyamine biosynthesis inhibitors, 
cells in culture can be deprived of polyamines which results in marked decreases 
in growth and proliferation [112].  Polyamines are proposed to function by 
preserving and increasing the stability of DNA structure in vivo through 
electrostatic interactions [113; 114].  These molecules are found in cells at high 
concentrations (millimolar for spermine and spermidine, while putrescine is 
slightly lower) [115].  Polyamine concentrations are highly regulated as 
evidenced by a complex network of enzymes, antizymes, and transporters which 
are used for intracellular synthesis, degradation, uptake and efflux of these 
molecules in vivo [116].  Deviations in homeostatic concentrations of polyamines 
have been shown to lead to cell death and have been described in several 
neurological disorders as discussed below.   
 
1.4.3. Altered polyamine levels in vivo 
 In contrast to being necessary for cell growth, polyamines are also known 
to participate in programmed cell death or apoptosis which has been recognized 
for many years [117].  In somewhat of a paradox, it appears that polyamines act 
as protectors, modulators or even promoters of apoptosis [118].  Abnormally high 
polyamine levels in cells have been shown to cause apoptotic cell death [119; 
120].  Exposure to high concentrations of spermine and spermidine results in 
upregulation of polyamine oxidase (PAO), the enzyme responsible for 
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degradation of these polyamines.  Degradation results in the formation of 
aminoaldehyde metabolites from polyamines, which are known to be strong 
inducers of apoptosis [121].  One of these metabolites in particular, 3-
aminopropanal, has been shown to exert its toxic effects specifically on 
lysosomes by facilitating membrane rupture and leakage [122].  Interestingly, 
these effects are greatly enhanced in neuronal cells [123; 124].  Decreased 
levels of polyamines have been shown to induce apoptosis by a variety of 
mechanisms.  First, very low levels of polyamines available to DNA have been 
shown to lead to cell cycle arrest due to stoppage of DNA replication [125].  
Second, since polyamines bind to DNA, low levels result in destabilization of 
important cellular structures, like chromatin, which can become sensitized to 
nucleases and ultimately lead to cell death [126].  Thus, it appears that a delicate 
balance exists in cells between too little and too much intracellular polyamine 
concentration. 
                            
 In the case of polyamines, it is vitally important for the efficient 
regulation of homeostatic concentrations to avoid deleterious effects of increased 
or decreased cellular levels.  Since polyamines and their metabolites have been 
shown to localize within lysosomes, the inefficient release of lysosome contents, 
as observed in NP-C disease, may result in concentration imbalances and 
neurological dysfunction.  Investigations concerning NP-C disease pathology and 
polyamines have been lacking; however, there have been significant 
investigations of multiple neurodegenerative disorders similar to NP-C disease 
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[127].  These disorders include Alzheimer’s disease and multiple sclerosis, both 
of which have altered polyamine pools and/or deviant enzyme activities [128; 
129; 130].  
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1.5. Objectives of dissertation 
 The objectives of this work were to identify and characterize differences in 
lysosome trafficking of weakly basic amines between NPC1-deficient and 
competent cells with the overall goal of elucidating a novel function for this 
intriguing protein.  The following studies were carried out to address this goal and 
are discussed in detail in the following chapters: 
 
1. Elucidate the NPC1-mediated molecular events that are occurring in 
normal cells, but not in NP-C cells, which could permit efficient clearance 
of amines from lysosomes. 
 
2. Determine the role of NPC1 in the secretion of amines from lysosomes. 
 
3. Develop and employ methods to determine the influence of weakly basic 
amines on NPC1-mediated secretion of lysosome contents. 
 
4. Link NPC1-defective amine-trafficking to NP-C disease pathology using a 
physiologically relevant example of amine-induced toxicity in cells.   
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Evaluating the role of NPC1 in amine-induced vacuolization of lysosomes 
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2.1. Introduction 
It has been demonstrated repeatedly that the administration of certain 
weakly basic compounds to cells in culture results in the formation of large 
vacuoles of lysosomal origin that are visible by conventional light microscopy.  
These vacuoles are known to form due to the hyperaccumulation of weak bases, 
also known as lysosomotropics, in the lysosomal lumen.  The pH-partitioning 
type mechanism by which these weakly basic molecules enter lysosomes has 
been described elsewhere [1; 2] (Chapter 1).  Briefly, the accumulation of weakly 
basic compounds in lysosomes is based on the following assumptions: 1) neutral 
forms of weakly basic compounds can passively diffuse through lipid bilayers 
such as the plasma membrane and the limiting lysosomal membrane.  2) The 
ionized forms of these compounds cannot, to a significant degree, diffuse back 
through the membranes.  3) There exists a pH gradient between the cytosol and 
lysosome, in which the pH of the lysosome is considerably lower [3; 4; 5].  As a 
consequence, the formation of a weak base concentration gradient between 
lysosomes and the cytosol will occur. 
 
In 1981, Okhuma and Poole suggested that the presence of a weak base 
concentration gradient between lysosomes and cytosol would result in osmotic 
stress being applied to the lysosome membrane [6].  Ultimately, they proposed 
that an influx of water into the lysosome occurs to dissipate the concentration 
imbalance leading to increased organelle volume and the formation of a large 
cytoplasmic vacuole.  However, several lines of evidence have suggested that 
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osmotic stretching of lysosome membranes to facilitate organelle expansion is 
not a probable mechanism of amine-induced vacuolization [7; 8; 9].  Experiments 
using agents which inhibited microtubule networks in cells showed that vacuoles 
did not form after weak base administration [9].  The dependence of an intact 
microtubule network on the formation of amine-induced vacuoles suggests that 
lysosomes are recruiting membrane components (i.e. from other organelles) to 
facilitate organelle size increase.  Furthermore, Solheim et al., compared the 
rates of amine clearance from cells with the time it took for the vacuolized 
lysosomes to return to normal size [7].  The authors argued that if vacuolization 
was caused by osmotic stretching, then the rate of amine depletion from 
lysosomes should parallel the rate of reduction in organelle size. This work had 
shown that complete amine depletion from cells significantly preceded the 
reduction in organelle size and therefore provided strong evidence supporting the 
requirement for membrane recruitment in the vacuolization process. 
 
Although the basis for accumulation of weak bases has been thoroughly 
described, the cellular components that allow vacuolization to occur are poorly 
understood.  Previous research in our laboratory suggested that the lysosome 
membrane protein Niemann-Pick C1 (NPC1) played a critical role in the uptake 
and clearance of weakly basic amines [10]. To expand on this area and evaluate 
if NPC1 was necessary for the amine-induced vacuolization of lysosomes we 
have evaluated the uptake and distribution of model weakly basic amines in 
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normal fibroblasts and fibroblasts that possess a mutated and dysfunctional form 
of the NPC1 protein. 
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2.2. Materials and methods 
2.2.1. Antibodies and reagents 
Anti-EEA1 (early endosomes), anti-golgin-84, and anti-GM130 (Golgi 
apparatus) mouse monoclonal antibodies were obtained from BD Biosciences 
(San Jose, CA).  Mouse monoclonal anti-mannose 6-phosphate receptor (MPR, 
late endosomes) and β-actin antibodies were obtained from Abcam (Cambridge, 
MA).  Mouse monoclonal anti-LAMP-1 (lysosomes) antibody was purchased from 
Developmental Studies Hybridoma (Iowa City, IA).  Rabbit polyclonal anti-NPC1 
antibody was obtained from Novus Biologicals (Littleton, CO).  Alexa Fluor 647 
dextran and goat anti-mouse and anti-rabbit secondary antibodies, biotinylated 
dextran amine, and Alexa Fluor 555 and 647 succinimidyl esters were obtained 
from Invitrogen (Eugene, OR).  Carboxylate-modified polystyrene beads were 
purchased from Polysciences (Warrington, PA).  siRNA specific to NPC1 was 
custom synthesized by Ambion (Austin, TX).  NPC1-GFP and Rab9-YFP plasmid 
DNA were kindly provided by Dr. Matthew Scott and Dr. Suzanne Pfeffer of 
Stanford University School of Medicine (Stanford, CA).  Transfection reagents for 
siRNA (siPORT-amine) and plasmid DNA (FuGene6) were purchased from 
Ambion and Roche (La Jolla, CA) respectively.  All other materials, unless 
otherwise stated, were acquired from Sigma-Aldrich. 
 
2.2.2. Cell culture and conditions 
Normal human fibroblasts (CRL-2076, designated NPC1+/+) were cultured 
according to Coriell Cell Repository’s (Camden, NJ) suggestions.  Niemann-Pick 
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Type C disease (NP-C) fibroblasts were obtained through ATCC.  These 
fibroblasts possess a mutated npc1 gene coding for two amino acid substitutions 
(P237S and I1061T) which results in a dysfunctional NPC1 protein (GM-03123, 
designated NPC1–/–) [11]. NPC1–/–, mucolipidosis type IV (GM-02408, designated 
MLIV), and Sandhoff’s disease (GM-11707) fibroblasts were all cultured 
according to ATCC (Manassas, VA) instructions.  All media was supplemented 
with 10% FBS and 1% penicillin/streptomycin.  Cultures were maintained at 37oC 
in a humidified 5% carbon dioxide atmosphere.  For all experiments, cells were 
used before passage 5 and plated 24 hrs prior to evaluations to permit 
adherence. 
 
2.2.3. Western blot analysis and densitometry 
Western blots were performed as previously described in our laboratory 
[12].  First, post-nuclear supernatant (PNS) proteins were separated by SDS-
PAGE using 7.5% bis-acrylamide gels.  Proteins were then transferred to 0.45 
µm nitrocellulose membranes for 2 hrs at 100V for every sample except those 
identifying MPR expression which were transferred for 3 hrs.  Membranes were 
blocked overnight at 4oC with 5% milk in Tris-buffered saline (TBS) 
supplemented with 0.5% Tween-20 at pH 7.4.  Primary antibodies specific to 
proteins of interest were incubated in 5% milk in TBS for 2 hrs.  β-actin primary 
antibodies were included to control for protein loading (all primary antibodies 
were diluted 1:250 in 5% milk-in-TBS).  Secondary HRP-conjugated antibodies at 
1:1000 dilutions in 5% milk in TBS were subsequently incubated for 2 hrs.  
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Enhanced chemiluminescence (ECL) reagents were used to illuminate protein 
bands which were visualized by exposure to Kodak Biomax film.  All steps were 
performed at room temperature unless otherwise stated.   
 
For densitometry, exposed films were scanned and converted into 
greyscale JPEG images.  Using ImageJ software, images were corrected for 
background (Analyze>Calibrate>Function>Uncalibrated OD).  Next, bands were 
selected by drawing a rectangle encompassing the band and selected as the first 
band (Analyze>Gels>Select First Lane).  These bands were then plotted 
(Analyze>Gels>Plot lanes) and the area under the curve measured.  This 
procedure was then repeated for each band of interest.  For comparison between 
samples, band areas were normalized to their respective actin band for each 
lane and expressed as a percentage.     
  
2.2.4. Amine-induced vacuole size determinations 
A confocal microscopy method was developed to obtain average 
diameters of NR-containing compartments.  Briefly, cells were treated with 50 µM 
nocodazole (NOC) for 1 h, washed with PBS (3X) and then exposed to 70 µM 
neutral red (NR) in culture medium for 6 hrs.  Cells without NOC pretreatment 
were included as positive controls for NR-induced vacuolization.  Fibroblast 
monolayers were viewed with a Zeiss Meta 510 confocal microscope equipped 
with an argon laser set at 458 nm for transmission.  Images were captured with a 
Hamamatsu Orca ER camera using identical magnification settings for each 
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image.  For size determination, NR-containing compartments were measured 
using the line and measure area functions in MetaMorph software version 7.0 
from Universal Imaging Corporation (Downington, PA).  The diameters of 150 
NR-containing vesicles from 3 separate experiments were averaged. 
 
2.2.5. Silencing of NPC1 protein expression using siRNA 
An siRNA construct was utilized to silence NPC1 expression as previously 
reported [13].  NPC1 was targeted using siRNA against the following mRNA 
sequence: CCAGGTTCTTGACTTACAA.  Non-specific scrambled siRNA 
(Ambion Austin, TX) was used as a negative control under identical transfection 
conditions per the manufacturer’s suggestions.  All siRNA transfections were 
performed using the siPORT-amine transfection reagent (Ambion) for 72 hrs.  To 
confirm NPC1 knockdown, cells were harvested post-transfection and lysates 
subjected to Western blot analysis.  Relative band intensities of NPC1 were 
determined using densitometry with ImageJ software.  For siRNA experiments 
requiring subsequent amine exposure, transfections were performed as 
described, at which point cells were exposed to 70 µM NR or 100 µM chloroquine 
for 6 hrs. 
 
2.2.6. Immunofluorescence 
Cells were seeded in 8-well culture slides at 50,000 cells per well the day 
before experimentation to allow for adherence.  Fibroblasts were fixed using 
freshly prepared 4% paraformaldehyde in PBS for 20 mins and washed 1X with 
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PBS.  Cells were then permeabilized using a solution of PBS containing 0.1% 
saponin and 10% FBS for 30 mins.  Primary and secondary antibody solutions 
were made in 0.05% saponin and 10% FBS in PBS.  Cells were incubated with 
primary antibodies for 2 h using the following dilutions: EEA1 (1:50); MPR (1:50); 
LAMP-1 (1:100); NPC1 (1:100); and GM130 (1:100).  Cells were subsequently 
washed with PBS (3X) and secondary antibodies (Alexa Fluor 647 conjugated 
anti-mouse or rabbit IgG, 1:1000) were applied for 2 h.  Cells were washed again 
with PBS (4X) prior to microscopy (Nikon Eclipse 80i).  Images were acquired 
with a Nikon Eclipse 80i equipped with standard PlanFluor 60X epifluorescence 
optics and a Hamammatsu Orca ER camera.  Cy5 filter sets (Nikon Cy5-HyQ, 
Brattleboro, VT) were employed for visualization of Alexa Fluor 647.  All steps 
were carried out at room temperature unless otherwise noted.   
 
2.2.7. DNA transfections 
Functional NPC1-GFP and Rab9-YFP plasmid DNA [14; 15] were 
amplified using Novablue gigacompetent E. coli cells (Novagen-EMD 
Biosciences, San Diego, CA) and selected using 30 ug/mL kanamycin in 
lysogeny broth (0.5% yeast extract, 1.0% peptone, 1.0% sodium chloride).  DNA 
was subsequently purified using the Midipreps system from Promega (Madison, 
WI).  DNA was quantified by measuring absorbance at 260 nm using a Cary 100 
Bio spectrophotometer.  DNA to protein ratios (A260/A280) for purified plasmid 
stocks were approximately 1.8-2.0.   
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Transfections were performed using FuGene6 (Roche, Indianapolis, IN) 
per the manufacturer’s suggestions.  This included FuGene6 to DNA ratios of 8:2 
and 3:1 for NPC1-GFP and Rab9-YFP respectively.  For dual transfected cells, 
DNA was mixed to give appropriate ratios.  Transfections were carried out for 48 
hrs to allow adequate protein expression in fibroblasts.  To assess the effects of 
amine exposure on single and dual transfected cells, 100 µM chloroquine was 
added post-transfection to the culture medium for 6 hrs.  Microscopy was then 
performed using standard epifluorescence optics (Nikon) as described above.  
For fluorescent imaging of GFP/YFP in dually transfected cells, filter sets specific 
to GFP and YFP were employed (Chroma, GFP-31019 and Semrock Brightline 
YFP-2427A).  
 
2.2.8. Isolation and characterization of amine-containing vacuoles 
Lysosomes were isolated using a previously described magnetic 
chromatography approach [12; 16].  The isolation procedure, as well as control 
experiments, was performed as previously described with minor modifications to 
allow for localization of the superparamagnetic iron dextran (FeDex) in 
lysosomes of amine treated adherent cells.  FeDex was prepared as described 
[16]. Briefly, fibroblasts (5 x 107) were grown to 80% confluence before 
incubation with 2 mg/mL FeDex for 2 hrs at 37oC.  Cells were then washed with 
warm PBS (4X) and chased in FeDex free media for 20 hrs at 37oC to permit 
FeDex localization to lysosomes.  Subsequently, FeDex containing cells were 
washed with ice-cold PBS (2X) and homogenized in 0.75 mL of a hypotonic 
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buffer containing 15 mM potassium chloride, 1.5 mM magnesium acetate, 1 mM 
dithiothreitol and 10 mM Hepes (pH = 7.4).  This buffer was supplemented with 
protease inhibitors (0.1 mM phenyl-methyl sulfonyl fluoride and 1 µg/mL of 
aprotin, leupeptin and pepstatin) on the day of isolation.  Cells were 
homogenized using a glass dounce homogenizer with 20 strokes to permit at 
least 80% cell breakage.  Immediately after homogenization, 0.25 mL of a 
hypertonic buffer containing 375 mM potassium chloride, 22.5 mM magnesium 
acetate, 1 mM dithiothreitol and 220 mM Hepes (pH = 7.4) was added.  The 
homogenate was then centrifuged at 2,000 rpm for 10 min to pellet nuclei and 
intact cells.  The resulting post-nuclear supernatant (PNS) was then applied to a 
magnetic column (25-MS miniMACS, Miltenyi Biotec, Auburn, CA).  The column 
had been previously equilibrated with a solution of bovine serum albumin (0.5%) 
for 10 min to discourage non-specific protein binding.  After the PNS was passed 
through the column (flow through was kept for later analysis), 1 mL of 0.5 mg/mL 
DNase I was incubated in the column for 10 min.  The column was then washed 
with 1 mL of PBS and eluted with 0.7 mL of 0.5% Triton X-100 that was 
incubated in the column for 10 min.  To characterize the isolated fraction for 
purity and protein content, Western blot analysis was performed.  
 
To confirm that FeDex was localizing in amine containing compartments, 
cells were incubated with 2 mg/ml Alexa Fluor 647 dextran in PBS for 2 hrs, 
washed with PBS (4X), and subsequently given chase in complete dextran-free 
medium for 20 hrs at 37oC.  Cells were then exposed to 100 µM CQ for 6 hrs.  
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Phase contrast and fluorescence images were taken and merged using 
MetaMorph software. 
 
2.2.9. Sucrosome formation 
Sucrosomes were formed by culturing cells in complete medium 
containing 0.1% sucrose for 48 hrs. 
 
2.2.10. Late endosome-lysosome fusion assay 
 The fusion between late endosomes and lysosomes was evaluated in 
fibroblasts using a method described by Jahraus et al. [17] with modifications to 
allow quantitative assessments based on fluorescence resonance energy 
transfer (FRET) of late endosome/lysosome contents upon fusion.  To 
accomplish this, biotinylated dextran, fluorescently labeled with Alexa Fluor 647 
(FRET acceptor), was localized to lysosomes using the above optimized 
pulse/chase scheme for dextran (Section 2.2.8).  Next, streptavidin-conjugated 
latex beads (0.792 ± 0.037 µm), fluorescently labeled with Alexa Fluor 555 
(FRET donor), were localized to late endosomes for 2 hrs per Jahraus et al. [17].  
To detect fusion, FRET measurements were made using a Photon Technologies 
International (Birmingham, NJ) Ratiomaster microscope-mounted 
spectrofluorimeter with PMT detection.  Complete details on experimental design, 
tracer construction, control measurements and analysis can be found in 
Appendix I. 
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2.3. Results 
2.3.1. Amine-induced vacuolization of lysosomes requires functional NPC1 
We examined if NPC1 was involved in the amine-induced vacuolization of 
lysosomes.  Human foreskin fibroblasts (normal or with a mutated and 
dysfunctional NPC1, represented by NPC1+/+ and NPC1-/-, respectively) were 
incubated with the lysosomotropic amine neutral red (NR) and high resolution 
images of cells were taken with a confocal microscope to examine the average 
diameter of NR-containing compartments.  Normal cells exposed to NR had an 
approximate vacuole size of 1.5 µm (Fig. 2.1A, B).  Exposed NPC1-/- cells had 
NR-containing compartments approximately one half the size of those from 
NPC1+/+ cells.  NPC1+/+ cells treated with nocodazole also had small NR-
containing vacuoles. This illustrates the involvement of microtubules in 
vacuolization, suggesting that the membrane is not obtained, at least 
significantly, from internal sources such as multi-vesicular bodies.   
 
To more specifically illustrate that amine-induced vacuolization was 
NPC1-dependent, we utilized a small interfering RNA (siRNA) designed to 
transiently suppress the expression of NPC1 in normal cells.  This was confirmed 
experimentally in NPC1+/+ cells by Western blot analysis (Fig. 2.2A).  When 
performing the siRNA transfections, we were sometimes able to view, on a single 
image, cells that were not efficiently transfected (i.e. normal NPC1 expression) 
alongside those that were efficiently transfected and had depleted NPC1.  
Immunofluorescence staining of NPC1 allowed us to demonstrate that only cells  
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expressing NPC1 formed amine-induced vacuoles (Fig. 2.2B).  Conversely, cells 
that did not have visible amounts of NPC1 did not form the amine-induced 
vacuoles.  We were also able to rescue the amine-induced vacuolization 
phenotype in NPC1-/- fibroblasts by transfection with a functional NPC1-GFP 
construct (Fig. 2.3).  To control for the possibility that cholesterol accumulation 
could be affecting the ability of lysosomes to vacuolize when exposed to NR, we 
utilized two more cell lines with lysosomal storage disorders, Sandhoff’s disease 
and mucolipidosis type IV (MLIV).  Both of these lysosome storage disorders 
result in the accumulation of multiple lipids, including cholesterol, in the 
lysosomal lumen as shown by cholesterol staining with filipin (Fig. 2.4A).  
However, both of these cell lines exhibited a normal lysosome vacuolization 
phenotype when compared to normal cells exposed to NR (Fig. 2.4B).  
Collectively, these results illustrate the requirement for NPC1 in the amine-
induced vacuolization of lysosomes. 
 
2.3.2. Amine-induced vacuoles are formed through a heterotypic fusion of 
lysosomes with late endosomes. 
It is important to realize that amine-induced vacuolization requires the 
recruitment of membranes to allow lipid bilayers to expand [7].  This is consistent 
with our previous results that illustrated the requirement of intact microtubules in 
this process (Fig. 2.1).  Accordingly, we sought to characterize the properties of 
the vacuole.  Initially, we examined if amines facilitated the fusion of lysosomes 
with other organelles or vesicles. Immunofluorescence analysis of  
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NPC1+/+ fibroblasts demonstrated that without amine treatment NPC1 is shown to 
reside predominantly on a subset of LAMP-1 (a lysosome-specific membrane 
protein) positive lysosomes and not to a significant extent on late endosomes 
containing the cation-independent mannose 6-phosphate receptor (MPR) (Fig. 
2.5).  However, when NPC1+/+ cells were treated with NR the resultant vacuoles 
contained LAMP-1, MPR, and the NPC1 protein (Fig. 2.6).  The vacuoles did not 
colocalize with a Golgi-specific protein GM130 or with the early endosome 
antigen-1 (EEA1) an early endosome specific protein (Fig. 2.6).  Importantly, the 
exposure of NPC1-/- cells to NR had no effect on LAMP-1 or MPR distribution.  
The two markers were found in distinct organelles pre and post-amine treatments 
(Fig. 2.7).     
 
To further confirm the colocalization of late endosome markers with 
lysosome markers observed with immunofluorescence microscopy, organelle 
isolations and Western blot analysis was performed.  Terminal endocytic 
compartments (native lysosomes and vacuoles) were purified from fibroblasts 
using a previously described magnetic chromatographic approach that utilizes 
endocytosed iron-coated dextran (FeDex, 10,000 MW) [12].  To ensure FeDex 
was localizing with amine-induced vacuoles using optimized pulse-chase 
parameters, a fluorescence-labelled dextran of the same size was incubated with 
cells (Fig. 2.8A).  Significant fluorescence was observed in chloroquine-induced 
vacuoles suggesting similar behavior by FeDex.  Western blot analysis revealed 
that in the absence of amines, the isolated compartment was highly enriched in  
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the lysosomal protein LAMP-1 and was not significantly contaminated with other 
compartments such as the Golgi (Golgin-84) or early endosomes (EEA1) (Fig. 
2.8B).  These protein bands were observed in post nuclear supernatant (PNS) 
and column flow through fractions.  The isolated compartment was analyzed for 
the presence of MPR, which was shown to become enriched only in NPC1+/+ and 
not in NPC1-/- fibroblasts that were treated with amines prior to the isolation (Fig. 
2.8C).  These results confirm previous observations using immunofluorescence 
microscopy (Fig. 2.6).  
 
MPR has been shown to redistribute to other organelles in response to 
exogenous treatments, which might lead to the false observation of late 
endosome colocalization with lysosomes [18; 19].  To confirm that late 
endosomes were involved with vacuolization and membrane recruitment in living 
cells, NPC1+/+ fibroblasts were co-transfected with Rab9-YFP, another late 
endosome specific protein, and with NPC1-GFP for lysosomes.  Consistent with 
prior results, colocalization of these proteins occurred extensively on amine-
induced vacuoles, although a much smaller degree of colocalization was 
observed in cells not incubated with the amine chloroquine (Fig. 2.9).  
Collectively, these findings provide strong evidence that amine-induced vacuoles 
are the result of lysosome and late endosome fusion.   
 
We next evaluated whether NPC1 was required for any vacuolization 
event involving lysosomes or if it was specific to vacuolization induced by  
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amines. It is well known that lysosomes can be vacuolated by incubating cells in 
high concentrations of sucrose [20].  The resultant vacuoles are referred to as 
sucrosomes.  Interestingly, the formation of sucrosomes occurred regardless of 
NPC1 functional status (Fig. 2.10).  This result suggests that sucrose-induced 
vacuolization occurs by a different mechanism, independent of NPC1.  Moreover, 
formation of sucrosomes did not appear to involve fusion of late endosomes with 
lysosomes since MPR and LAMP-1 did not significantly colocalize when 
observed with immunofluorescence (Fig. 2.10).  This is consistent with previous 
findings which stated that sucrose-induced vacuoles were primarily formed from 
homotypic lysosome-lysosome interactions and not heterotypic fusion events 
[21]. 
 
Late endosomes and lysosomes have been shown to interact in normal 
cells without amine treatments [17; 22; 23].  Previously we had shown that 
amine-induced vacuoles were formed from the fusion of late endosomes with 
lysosomes and this phenomenon did not occur in NPC1 deficient cells (Figs. 2.7 
and 2.9).  Next, we investigated if NPC1 was involved in the fusion of lysosomes 
and late endosomes without amine treatments.  To evaluate this possibility, a 
method for quantitatively determining these events in our NPC1 fibroblast model 
was developed and is described in Appendix I.  Briefly, using optimized pulse-
chase conditions (see Appendix I) we localized biotin-dextran into lysosomes and 
streptavidin-coated latex beads into late endosomes.  Each of these probes was 
labelled with a different fluorophore that could be used for fluorescence 
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resonance energy transfer (FRET)-based evaluations if the two organelles were 
to interact and mix contents.  We observed, through the appearance of FRET 
signal over time, that lysosomes and late endosomes were interacting in NPC1 
competent cells without amine treatments (Fig. 2.11).  Furthermore, NPC1-/- cells 
showed no increase in FRET signal over time which indicated little to no late 
endosome-lysosome interactions was occurring in these cells. 
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2.4. Discussion 
 Since the discovery of the lysosome by Christian De Duve, there has been 
a significant amount of research done to understand weak base sequestration in 
lysosomes and how this accumulation contributes to vacuolization.  The basis for 
weak base accumulation in lysosomes has long been theoretically accepted, 
although the mechanism for vacuolization is still poorly understood.  Previously, it 
was thought that vacuolization occurred due to an osmotic expansion, whereby 
an influx of water into the organelle would help to dissipate the weak base 
concentration gradient [6].  Such a mechanism would justify the increase in 
organelle volume and has been observed for hyper-osmotic molecules such as 
sucrose [21].  Since lysosomes and late endosomes are multi-vesicular, meaning 
they have multiple membranous structures within one organelle; the osmotic 
stress would induce these vesicular structures to fuse with the limiting lysosome 
membrane resulting in a larger organelle.  Although osmotic stress is not 
precluded from weak base accumulation in lysosomes, the formation of large 
vacuoles has been shown to be microtubule dependent, which suggests that the 
recruitment of membrane to the lysosome from other sources is necessary for 
organelle expansion (Fig. 2.1).   
 
In this chapter, we have provided evidence that the amine-induced 
vacuolization of lysosomes observed in human fibroblasts is facilitated by the 
heterotypic fusion of lysosomes with late endosomes in an NPC1-dependent 
manner.  In support of this, Arai et al. have described a cell-free system that  
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shows lysosomes resuspended in isotonic buffer can osmotically rupture when 
exposed to weakly basic amines if not incubated with cell cytosol containing 
intact organelles [8].  The authors argue that the presence of cytosol provides the 
re-suspended lysosome solution with more lysosomes or possibly late 
endosomes for interaction.  These interactions would help to dissipate the amine 
concentration gradient in lysosomes since the recruitment of late endosomes 
would increase the volume of the organelle.  Although Arai et al. speculated that 
these events were occurring; the interaction of lysosomes with late endosomes 
has been well documented in the literature.  Bright et al. has observed transient 
interactions between the two organelles in living cells using fluorescence and 
electron microscopy [22; 24].  Mullock et al. has described in great detail the 
ability of lysosomes to fuse with late endosomes in vivo and in vitro [25; 26].  
They have observed, using transmission electron microscopy, these interactions 
occurring and have used a cell-free system to describe necessary protein 
components.  In a similar fashion, we have used a FRET-based method to show 
that NPC1 is required for the interaction of lysosomes with late endosomes (Fig. 
2.11).     
At present, there is limited information on the proteins required for the 
amine-induced vacuolization process to occur.  It has been reported that the 
function of the vacuolar-ATPase (V-ATPase) is necessary for vacuolization [27].  
This seems reasonable since disruption of the pH gradient between the cytosol 
and the lysosome should not permit increased weak base accumulation. 
Experiments using purified VacA, a non-amine toxin excreted from  
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pylori, which vacuolizes lysosomes via late endosome fusion, have provided 
insight into vacuolization mechanisms.  Using VacA it was shown that Rab7 
(GTPase tether) and VAMP-7 (a SNARE protein) are necessary for vacuolization 
to occur [28; 29].  By transfecting cells with plasmid DNA encoding for mutated 
Rab7 or siRNA specific to syntaxin-7 (another SNARE protein), vacuolization 
was inhibited upon administration of VacA.  Since the function of both of these 
proteins is to aid in organelle fusion in vivo [30; 31], these findings support 
membrane recruitment to facilitate vacuolization of lysosomes. 
 
The lysosome is now understood to be a dynamic organelle capable of 
interacting with other compartments of the cell.  The findings presented here 
provide evidence in support of these observations and suggest that without a 
functional NPC1 protein amine-induced vacuolization cannot occur.  NPC1 
appears to be mediating lysosome expansion by facilitating the fusion of late 
endosomes with lysosomes.  
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Chapter 3 
 
 
 
Evaluating the role of NPC1 in vesicle-mediated amine clearance from lysosomes 
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3.1. Introduction 
Traditionally, the lysosome has been considered the terminal 
compartment for materials endocytosed into cells [1].  However, research has 
shown that materials either endocytosed into lysosomes or ion-trapped by pH-
partitioning can be efficiently released to the cell periphery [2].  Although the 
mechanism of fluid phase endocytosis and weakly basic amine sequestration in 
lysosomes has been well-described by our lab and others [3; 4; 5], the 
mechanism for the efflux of lysosome contents is poorly understood.  
Considering the high concentrations of amines that can sequester into 
lysosomes, mechanisms must exist for their removal to avoid toxic effects such 
as lysosome rupture. 
 
In this chapter, we attempt to identify Niemann-Pick C1 as a necessary 
protein for the trafficking of amines from the lysosome.  Previous research has 
shown that defects in Niemann-Pick C1 (NPC1) activity result in the inefficient 
secretion of multiple lysosome cargos.  To date, LDL-derived unesterified 
cholesterol, sphingomyelin, glycolipids and phospholipids have been shown to 
accumulate in the lysosomal lumen of NP-C disease cells in vivo [6; 7; 8; 9].  The 
clearance of endocytosed lysosome probes, such as radioactive sucrose, is also 
been impeded by NPC1 dysfunction [10].  Although defects in the clearance of 
membrane impermeable molecules in NP-C disease cells have been described, 
research investigating the proteins required for efficient efflux of amines from 
lysosomes is lacking. 
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In an attempt to describe NPC1 involvement in small molecule amine 
transport, it was recently reported that NPC1 shares significant structural 
homology with a family of prokaryotic permeases [11].  From this homology, 
Davies et al. proposed that NPC1 may function in intracellular drug transport as a 
membrane transporter, similar to P-glycoprotein.  To test this hypothesis, the 
authors monitored the efflux of acriflavine, a fluorescent small molecule amine 
that localizes to lysosomes.  The authors concluded that acriflavine was cleared 
from lysosomes by NPC1-mediated translocation from the lumen to the cytosol.  
However, the implication of NPC1 acting as a molecular transporter (i.e. a P-gp 
like pump or flippase) of acriflavine has since been discredited [12].  Our 
laboratory has shown that the functional status of NPC1 could influence the 
release of trapped weakly basic drugs from lysosomes to the extracellular space 
by a novel vesicle mediated microtubule-dependent pathway [2].  In this study, 
we observe that cells with mutated and dysfunctional NPC1, such as the multi-
drug resistant human leukemic cell line 60 (HL-60/MDR), are inefficient at 
clearing the weakly basic anti-cancer agent daunorubicin from lysosomes when 
compared to cells with functional NPC1.  Furthermore, when normal cells are 
treated with the microtubule destabilizer nocodazole, amine clearance is 
diminished [2].  These findings are in agreement with NPC1 facilitating removal 
of amines from lysosomes by a vesicle pathway and not by direct translocation 
across lipid membranes.       
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The work described in this section serves to specifically confirm the 
dependence on functional NPC1 for the efficient trafficking of lysosomal contents 
from lysosomes, in particular, trapped weakly basic amines.  Previous 
evaluations in HL-60/MDR cells were important for identifying NPC1 involvement 
in amine transport from the lysosome; however, in comparative evaluations using 
diseased cells, such as HL-60 or NP-C cells, there can be factors influencing 
clearance behavior that may not be due to protein malfunction.  For example, the 
clearance defects observed in NP-C cells could be due to the hyperaccumulation 
of lipids in the lysosome lumen.  To address these questions, we have sought to 
specifically silence NPC1 in normal cells, as well as evaluate lipid accumulation 
effects on the clearance of lysosome contents.   
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3.2. Materials and methods 
3.2.1. Reagents 
 [3H]-dextran (70,000MW; 125 µCi/mg) was purchased through American 
Radiolabeled Chemicals (St. Louis, MO).  Scintiverse-BD liquid scintillation 
cocktail was obtained from Fisher Scientific (Pittsburgh, PA) and neutral red (NR) 
from Sigma-Aldrich (St. Louis, MO).  Alexa Fluor 488 dextran and Lysotracker 
Red DND-99 (LTR) was obtained from Invitrogen (Eugene, OR).  siRNA specific 
to NPC1 was custom synthesized by Ambion (Austin, TX).  All other reagents 
unless otherwise specified were purchased through Sigma-Aldrich. 
 
3.2.2. Cell culture and conditions 
Normal human fibroblasts (CRL-2076, designated NPC1+/+) were cultured 
according to Coriell Cell Repository’s (Camden, NJ) suggestions.  Niemann-Pick 
Type C disease (NP-C) fibroblasts (NPC1–/–) were obtained through the ATCC.  
NPC1–/–, mucolipidosis type IV (GM-02408, designated MLIV), and Sandhoff’s 
disease (GM-11707) fibroblasts were all cultured according to the ATCC 
(Manassas, VA) instructions.  All media was supplemented with 10% FBS and 
1% penicillin/streptomycin.  Cultures were maintained at 37oC in a humidified 5% 
carbon dioxide atmosphere.  For all experiments, cells were used before 
passage 5 and plated 24 hrs prior to evaluations to allow for adherence. 
 
3.2.3. Dextran secretion assay 
3.2.3.1. Fluorescent dextran release 
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To qualitatively assess the clearance of endocytosed dextran, 
fibroblasts were plated in 8-well chamber slides at 3 x 104 cells per well 
and allowed to adhere overnight prior to incubating with 2 mg/mL Alexa 
Fluor 488 dextran for 2 hrs (in complete phenol red free DMEM).  Cells 
were washed with warm PBS (2X) and medium replaced.  Dextran was 
allowed to localize to lysosomes for 20 hrs at which point fluorescence 
images were acquired at different time points using standard 
epifluorescence optics (Nikon).   
 
3.2.3.2. Radioactive dextran release 
Fibroblasts were plated at 3 x 105 cells per well in 6-well culture 
plates and allowed to adhere overnight.  Cells were incubated with 50 
µCi/mL of [3H]-dextran in addition to 0.9 mg/mL cold dextran of the same 
molecular weight in complete medium at 37oC for 3 hrs and washed with 
warm media (4X).  Cells were then chased in dextran free media and the 
amount of [3H]-dextran secreted into the media was analyzed at indicated 
time points.  At the end of the assay, the fibroblast monolayer was 
dissolved using a solution of 50 mM Tris, 150 mM NaCl, and 1.0% NP-40 
to determine total dextran uptake of each well.  To address the non-
specific association of radioactive dextran with the cell monolayer on total 
amounts released, experiments were repeated at 4oC for 4 hrs (after the 
initial dextran incubation)and curve fit to obtain later data points.  These 
data points were subtracted from the same points from experiments 
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carried out at 37oC.  The cumulative amount of dextran released into the 
media is given as a percentage of the total amount of dextran 
endocytosed.  Quantitation of [3H]-dextran at each time point was 
performed using a liquid scintillation counter (Beckman LS5000; Beckman 
Coulter, Fullerton, CA) and Scintiverse-BD liquid scintillation cocktail. 
 
3.2.4. Silencing of NPC1 expression using siRNA.   
An siRNA construct was utilized to silence NPC1 expression as previously 
reported [13].  All siRNA transfections were performed using siPORT-Amine 
(Ambion) transfection reagent for 72 hrs as described previously (Section 2.2.5).  
For siRNA experiments requiring subsequent amine exposure, transfections 
were performed as described, at which point cells were exposed to 70 µM NR. 
 
3.2.5. Evaluating amine clearance from lysosomes 
3.2.5.1. Qualitative evaluations of amine clearance 
To qualitatively assess the clearance of sequestered model 
amines, cells were plated in 24-well plates (5 x 104 cells per well) and 
allowed to adhere overnight prior to incubation with either 70 µM NR for 6 
hrs or 2 µM LTR for 1 h.  After the incubation, cells were washed with PBS 
(3X) and chased with complete amine-free culture medium.  Images were 
then taken at various time-points using a Nikon TE-2000U inverted 
microscope for NR and an upright epifluorescent microscope (Nikon 
Eclipse 80i) with a Texas Red filter set (Nikon, HQ:TR) for LTR.  For 
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quantitatively evaluating the secretion of model amines, methods were 
developed as described below:  
 
3.2.5.2. Neutral red release assay 
For the quantitation of neutral red in fibroblasts, a 
spectrophotometric method for determining the release of amines from the 
lysosomes of cells was developed.  Fibroblasts were seeded in 24-well 
culture plates at a density of 50 x 104 cells per well with a 500 µL total well 
volume.  Next, fibroblasts were exposed to 70 µM NR for 6 hrs at 37oC 
(5% CO2).  NR-containing medium was washed from cell monolayers with 
warm PBS (3X) and replaced with 500 µL of complete DMEM medium.  
Measurements were taken at different time-points after replacement with 
NR-free medium by washing cells again with PBS (3X) and extracting NR 
from each well with 100 µL of a solution containing 49% methanol and 1% 
acetic acid.  Samples were analyzed by measuring the absorbance at 540 
nm using a 96-well plate reader (Multiskan, Thermo Scientific).  For 
normalization of NR amounts to protein, the post-nuclear supernatant 
protein concentration of 50 x 104 cells was determined by the method of 
Bradford [14].  
 
 3.2.5.3. Lysotracker red release  
For the comparison of relative amounts of LTR in fibroblasts, a 
method for determining the release of amines from the lysosomes of cells 
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was developed using images taken during qualitative evaluations.  First, 
images were scaled for contrast and brightness using MetaMorph 
software (v. 7.0).  Next, images were analyzed using the “Measure 
Average Intensity” function.  Background was subtracted by using this 
function in a selected area devoid of cells and LTR.  Values were 
converted into percentages by dividing by the initial time point. 
 
3.2.6. Live-cell phase microscopy 
 Fibroblasts were seeded at 50 x 104 cells per well in 4-well culture slides.  
Cells were kept alive during experimentation using a temperature controlled 
environmental chamber (Bioscience Tools, San Jose, CA) which was 
supplemented with CO2 and water.  Cells were kept in focus during experiments 
using a Prior Pro-scan II x,y,z motorized stage with preset stage positions.  
Images were acquired at various time points using standard phase contrast 
optics on an inverted Nikon TE-2000U fluorescence microscope with white light 
exposure and a Coolsnap-CF color camera (Photometrics, Tuscon, AZ).  
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3.3. Results 
3.3.1. NPC1 is required for the efficient release of lysosome contents 
 The release of endocytosed fluid phase probes from lysosomes has been 
shown to be significantly diminished in cells with dysfunctional NPC1 [2; 10].  
Since there are many variants of NPC1-/- cell lines available to the research 
community, we investigated if these observations from cell lines used in previous 
evaluations extended to the NPC1-/- cells used for our studies.  To accomplish 
this, we employed both qualitative and quantitative evaluations to monitor 
lysosome secretion using fluorescent and radioactive dextran polymers , 
respectively.  We specifically localized dextran to terminal endocytic 
compartments using the previously described pulse-chase protocol used for iron 
dextran (Chapter 2, Section 2.2.8).  For qualitative evaluations, fluorescence 
imaging was performed on dextran containing cells at different wash-out times 
(Fig. 3.1).  A radioactive dextran assay developed previously for determining 
secretion rates in HL-60 cells was used for quantitative evaluations of dextran 
release as a function of time in both normal and NPC1-/- fibroblasts (Fig. 3.2) [2].  
In both qualitative and quantitative evaluations, NPC1-/- cells experienced 
inefficient release of dextran from lysosomes when compared to control cells.  
These results, in agreement with previous research, confirm that NPC1 is 
required for the efficient egress of lysosome cargo to the cell periphery. 
 
3.3.2. NPC1 is required for the efficient release of amines from lysosomes 
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We have previously shown that the release of protonated amines from 
lysosomes is significantly impeded in NP-C diseased fibroblasts relative to 
normal cells [2].  The use of fibroblasts from NP-C patients to study NPC1 
function is routinely done but could yield misleading results considering the 
multiple compensatory pathways that could be established.  To more specifically 
investigate the involvement of NPC1, we evaluated the trafficking of 
lysosomotropic amines from normal cells treated with siRNA to transiently 
deplete NPC1.  NPC1 siRNA treatment conditions were optimized to enable 
efficient suppression of NPC1 expression (Chapter 2, Section 2.2.5).  The 
release of two well-known lysosomotropic amines, neutral red (NR) and 
Lysotracker Red (LTR), was evaluated.  Using light microscopy and time-lapse 
video microscopy, we qualitatively showed that NR release was inefficient in NP-
C fibroblasts and normal cells transfected with NPC1 specific siRNA, respectively 
(Figs. 3.3 and 3.4).  This was confirmed using a quantitative NR-release assay.  
We observed that NR release was efficient in normal fibroblasts compared to 
NPC1 siRNA-treated normal fibroblasts (Fig. 3.5A).  The NR release profile from 
NPC1-/- fibroblasts was similar to NPC1 siRNA-treated cells as both cells were 
unable to clear greater than 50% of their initial NR.  Furthermore, we 
demonstrated the release of NR was dependent on a functional microtubule 
network by evaluating NR-release at 4oC (Fig. 3.5B).  At this temperature energy 
dependent processes, such as vesicle trafficking, are inefficient.   
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The release of the lysosomal vital stain LTR from NPC1+/+ and NPC1-/- 
cells, evaluated using fluorescence microscopy, provides visual evidence for the 
differences in release (Fig. 3.6A).  To ensure these visual differences in LTR 
fluorescence were not due to variations in image contrast or brightness, relative 
amounts of LTR were determined by measuring the pixel intensity, which is 
independent of contrast/brightness, of LTR images taken at 24 hrs (Fig. 3.6B).  It 
was determined that NPC1+/+ cells have little to no LTR present after 24 hrs, 
whereas, NPC1-/- retain 30-40% of LTR in lysosomes, confirming visual 
observations.   
 
3.3.3. Lysosomal accumulation of lipids does not affect amine release 
 It has been previously shown that the hyper-accumulation of lipids in 
lysosomes can impede organelle motility [15].  Considering this, it is possible that 
the decreased cellular clearance of amines observed with the NPC1-deficient cell 
line could be secondary to the lipid accumulation and not directly related to the 
inactivity of NPC1.  To examine this possibility, we visually examined the 
clearance of LTR and quantitatively determined NR release in two additional 
fibroblasts obtained from patients with other lysosomal lipid storage disorders, 
including mucolipidosis IV (MLIV) and Sandhoff’s disease.  Both of these 
disorders are characterized by the hyperaccumulation of gangliosides, 
sphingolipids and cholesterol [16; 17].  The cholesterol accumulation phenotype 
was confirmed for these cell lines in Chapter 2, Figure 2.4.   
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LTR clearance from both Sandhoff’s and MLIV cell lines using the same 
conditions was qualitatively evaluated.  Both cell lines efficiently cleared LTR 
from lysosomes as compared to NPC1+/+ cells (Fig. 3.7).  Quantitative 
evaluations using NR confirmed these results, as both MLIV and Sandhoff’s 
disease had NR profiles similar to normal fibroblasts (Fig. 3.8).  Since both MLIV 
and Sandhoff’s disease cell lines have functional NPC1, these results further 
support the specific involvement of NPC1 in the efficient efflux of amines from 
lysosomes. 
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3.4. Discussion 
 Contained in this chapter are evaluations that assess the ability of cells to 
efflux a variety of molecules, including dextran polymers and ion-trapped model 
amines, from lysosomes by an NPC1-mediated pathway.  We have concluded 
that NPC1 has a functional role in the general trafficking of lysosomal contents to 
the extracellular space.  However, the efflux pathway that NPC1 is mediating 
remains elusive.  Thus the question remains, what specific trafficking step is 
NPC1 dysfunction negatively affecting? 
 
  When considering lysosome secretion, there are two main possibilities for 
the microtubule-dependent egress of lysosome contents to the cell periphery: 1) 
direct lysosome fusion with the plasma membrane [18] and 2) lysosome 
interactions with other sub-cellular organelles that are capable of facilitating 
secretion to the plasma membrane [19].  The notion of lysosome secretion is 
relatively new.  As mentioned previously, the lysosome has traditionally been 
considered a terminal compartment that is incapable of interacting in a retrograde 
fashion with the plasma membrane or other cell organelles.  Recently, a 
significant amount of research has been done in the area of lysosome dynamics 
that provides evidence for each of these two mechanistic possibilities. 
 
Norma Andrews and colleagues have made significant contributions 
towards understanding the mechanisms of lysosome fusion with the plasma  
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membrane [18; 20].  They have shown that increases in free intracellular 
(cytosolic) calcium ion (Ca2+) levels stimulate lysosomal exocytosis [18; 21].  
Furthermore, fusion was dependent on synaptotagmin VII, a SNARE protein 
required for membrane fusion [22].  The extent of fusion was determined by 
measuring the activity of lysosomal enzymes, such as β-hexosaminidase, that 
were released into the medium, as well as, the presence of lysosome proteins 
(lgp120) on the plasma membrane.  Although Andrews and others have provided 
evidence for the existence of this secretory pathway, in the absence of high 
concentrations of exogenously supplied calcium ions the release of lysosomal 
enzymes is minimal [23].  If we assume that the lysosome-plasma membrane 
pathway is the sole contributor for lysosome exocytosis, then we would expect to 
see minimal radioactive dextran release in Figure 3.2 as demonstrated by the low 
amounts of lysosomal enzymes observed by Andrews.  However, we observe 
significant exocytosis of dextran into the cell culture medium in normal cells, thus, 
there must be another contributing mechanism by which dextran and trapped 
amines can escape lysosomes.   
 
Similar to work done by Andrews, J.P. Luzio and colleagues have 
described in detail the ability of lysosomes to fuse with other cellular components 
[24; 25].  In particular, Luzio has demonstrated that lysosomes can interact and 
fuse with late endosomes resulting in a hybrid organelle of intermediate 
properties.  These content mixing events have been described in cell-free 
systems, as well as, in living cells [25; 26]  The fusion of these organelles has 
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been shown to be dependent on a number of proteins, which to date include 
SNAP, SNARE, and Rab proteins, all of which are known to be involved in 
vesicle fusion [27].  From a trafficking perspective, Jahraus et al. has shown that 
lysosomes traffic their contents back to late endosomes in a retrograde manner 
and that this pathway is microtubule dependent [28].  The biological significance 
of these interactions is currently unknown; however, it has been proposed that 
this is one way that lysosome cargo can be released to the cell surface [19; 29].  
Late endosomes are known to transiently interact with the Golgi apparatus via a 
vesicle mediated mechanism to return receptors, such as mannose-6-phosphate, 
which are necessary for the targeting of some proteins to endosome/lysosome 
compartments [30; 31].  Importantly, the Golgi apparatus is well-known for its 
functional role in the transport of proteins to the plasma membrane via secretory 
vesicles [32].  Thus, the interaction of lysosomes with late endosomes may 
provide an indirect pathway for lysosomal cargo release.  In support of this 
mechanism, we have shown previously that these interactions can occur in 
normal cells treated with the model amine neutral red (Chapter 2, Section 2.6).  A 
significant amount of late endosome markers were found colocalized with 
lysosomes in response to amine treatment.  Furthermore, we showed that these 
interactions were NPC1 specific using siRNA and severely diminished in NP-C 
diseased cells using a FRET-based late endosome-lysosome fusion assay. 
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4.1. Introduction 
Our laboratory, as well as many others has shown the clearance of 
trapped molecules from lysosomes is severely impaired in NP-C disease cells [1; 
2; 3; 4].  Considering there are many examples of lysosome secretion pathways 
that require stimulation by a cargo or signal (see below) we asked: is there a 
“primary cargo” that regulates this NPC1-mediated lysosomal egress pathway?  
Thus, the objective of this chapter is to address the hypothesis that NPC1 is 
responding to lysosomotropic amines and regulating their concentrations in 
lysosomes. Furthermore, we provide evidence that the clearing of lysosome 
contents to the extracellular space is accomplished through a novel NPC1-
mediated lysosome-late endosome pathway. 
 
There exist specialized cells in which secretion of lysosome contents to 
the extracellular space can be stimulated [5].  These lysosomes are referred to 
as secretory lysosomes and differ very little in their properties compared to 
conventional lysosomes [6].  Cells that possess secretory lysosomes include 
neutrophils, platelets and mast cells among many others, which secrete 
chemoattractants, clotting factors and histamine, respectively [5; 7; 8; 9].  The 
signals and receptors that stimulate the release of these cargos have been 
identified and well characterized. 
 
For most cells, however, lysosomes are considered the terminal endpoint 
for endocytosis and are not regarded as secretory organelles.   In contrast to this, 
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we and others have shown that macromolecules (i.e. dextran) which localize to 
lysosomes, can efficiently escape to the cell periphery (Chapter 3, Figure 3.1 and 
3.2) [1; 10; 11].  Griffiths suggested that lysosomes can interact with late 
endosomes in vivo forming hybrid organelles [12].  The physiological relevance 
for the formation of hybrid organelles, according to Griffiths, is for lysosomes to 
deliver enzymes to late endosomes for the digestion of endocytosed materials.  
However, as a consequence of content mixing between the two organelles, other 
molecules such as dextran are delivered back to late endosomes [13; 14; 15].  
Although these results are novel, information concerning the signals or exact 
molecular stimuli that trigger trafficking events and ultimately the removal of 
these cargos from conventional lysosomes is lacking. 
 
In this chapter, we utilize a novel FRET assay for late endosome-
lysosome fusion to assess the ability of lysosomotropic amines to stimulate 
hybrid organelle formation in an NPC1-dependent manner.  From previous 
immuofluorescence data taken in the presence of NR, we hypothesize that the 
administration of lysosomotropic amines will lead to an increased rate of hybrid 
organelle formation.  Furthermore, we hypothesize that as a result of more late 
endosome-lysosome fusion events, there will be more secretion of lysosome 
contents to the plasma membrane.  To examine this possibility we will utilize a 
previously described radioactive dextran release assay in the presence of 
amines in both normal and NP-C cell lines [2]. 
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4.2. Materials and methods 
4.2.1. Reagents 
 [3H]-dextran (70,000MW; 125 µCi/mg) was purchased through American 
Radiolabeled Chemicals (St. Louis, MO).  Scintiverse-BD liquid scintillation 
cocktail and morpholine were from Fisher Scientific (Pittsburgh, PA).  Neutral red, 
imidazole, spermine, nocodazole and concanamycin A were obtained from 
Sigma-Aldrich (St. Louis, MO).  Imipramine, chlorpromazine and amiodarone 
were from MP Biomedicals (Solon, OH).  U18666A was from Biomol (Plymouth 
Meeting, PA).  Fura2-AM, Fura2 Imaging Calibration Kit, Lysotracker red DND-
99, rhodamine 123, biotinylated dextran amine, and Alexa Fluor 555 and 647 
succinimidyl esters were obtained from Invitrogen (Eugene, OR).  Carboxylate-
modified polystyrene beads were purchased from Polysciences (Warrington, PA).  
All other reagents unless otherwise specified were purchased through Sigma-
Aldrich. 
 
4.2.2. Cell culture and conditions 
Normal human fibroblasts (CRL-2076, designated NPC1+/+) and Niemann-
Pick Type C disease fibroblasts (NPC1–/–) were cultured as previously described 
(Chapters 2, Sections 2.2.2).  For all experiments, cells were used before 
passage 5 and plated 24 hrs prior to evaluations to permit adherence.  For 
assays requiring fluorescence measurements, phenol red-free DMEM medium, 
supplemented the same as regular DMEM, was used to minimize background 
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4.2.3. Western blotting and densitometry 
 Western blots were performed as previously described in our 
laboratory and as described in Chapter 2, Section 2.2.3.  β-actin primary 
antibodies were included to control for protein loading (all primary antibodies 
were diluted 1:250 in 5% milk-in-TBS).  Secondary HRP-conjugated antibodies 
were used at 1:1000 dilutions.  All steps were performed at room temperature 
unless otherwise stated.  Densitometry was performed as previously described in 
Chapter 2, Section 2.2.3.   
 
4.2.4. Dextran secretion assay 
Fibroblasts were plated at 3 x 105 cells per well in a 6-well culture plates.  
Cells were incubated with 50 µCi/mL of [3H]-dextran in addition to 0.9 mg/mL 
non-radioactive dextran of the same molecular weight in complete medium at 
37oC for 3 hrs and subsequently washed with warm media (4X).  Cells were then 
chased in dextran free media and the amount of [3H]-dextran secreted into the 
media was analyzed at indicated time points.  At the end of the assay, the 
fibroblast monolayer was dissolved using a solution 50 mM Tris, 150 mM NaCl, 
and 1.0% NP-40 to determine total dextran uptake in each well.  To address the 
non-specific association of radioactive dextran with the cell monolayer on total 
amounts released, experiments were repeated at 4oC after the initial dextran 
incubation at 37oC for 4 hrs and curve fit to obtain later data points.  These data 
points were subtracted from the same points from ex
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37oC.  The cumulative amount of dextran released into the media is given as a 
percentage of the total amount of dextran endocytosed.  Quantitation of [3H]-
dextran at each time point was performed using a liquid scintillation counter 
(Beckman LS5000; Beckman Coulter, Fullerton, CA) and Scintiverse-BD liquid 
scintillation cocktail.   
 
For assays that included treatments with various agents, given 
concentrations were incubated concomitantly with [3H]-dextran for 3 hrs, washed 
and chased as described.  Analysis and non-specific release correction were 
performed as described above. 
 
 
4.2.5. Cytosolic calcium concentration determination 
 Determination of cytosolic free calcium levels was performed in living cells 
using a membrane permeable derivative of the fluorescent calcium sensitive dye, 
FURA2 (FURA2-AM).  First, 50 x 104 cells were exposed to 2.5 µM FURA2-AM 
ester for 30 min at 37oC.  The uptake of FURA2 was observed to be similar in 
both normal and NP-C fibroblasts (data not shown).  The excitation spectra of 
FURA2 from 300-425 nm was taken using a Photon Technologies International 
(Birmingham, NJ) Ratiomaster microscope-mounted spectrofluorimeter with PMT 
detection.  Filters and dichroic mirrors specific to FURA2 (Chroma) were used for 
selection of FURA2 emission intensities. 
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 The excitation spectrum of FURA2 changes upon binding of free calcium 
ions in a concentration dependent manner [16; 17].  An example of this is seen in 
Figure 4.8A.  Using pre-made buffers with varying concentrations of free calcium 
ions in the presence of FURA2, we constructed a standard curve (see Fig. 4.8B).  
This was accomplished by taking the ratio of FURA2 emission intensities at the 
340 and 380 nm excitation wavelengths.  The ratio of 340/380 nm was then used 
to calculate unknown calcium concentrations with or without amine pre-
treatments.                    
  
4.2.6. Late endosome-lysosome fusion assay 
 The fusion between late endosomes and lysosomes was evaluated in 
fibroblasts using a method described by Jahrus et al. [13] with modifications to 
allow quantitative assessments based on fluorescence resonance energy 
transfer (FRET).  Assays were performed exactly as described in Appendix I and 
Chapter 2, Section 2.2.3.  Briefly, biotinylated dextran, fluorescently labeled with 
Alexa Fluor 647 (FRET acceptor) was incubated with 5 x 104 cells and localized 
to lysosomes using an optimized pulse/chase scheme for dextran.  Next, 
streptavidin-conjugated latex beads (0.792 ± 0.037 µm) fluorescently labeled with 
Alexa Fluor 555 (FRET donor) were localized to late endosomes per Jahrus et al. 
[13].  To detect fusion, FRET measurements were made using a Photon 
Technologies International (Birmingham, NJ) Ratiomaster microscope-mounted 
spectrofluorometer with PMT detection.  Experimental details can be found in 
Appendix I. 
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For treatments, cells were administered compounds immediately after the 
localization of the latex bead to the late endosome (after a 2 h pulse) by spiking 
in a known concentration of compound into the incubation medium.  
Fluorescence intensity measurements were initiated immediately thereafter.   
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4.3. Results 
4.3.1. Certain lysosomotropic amines stimulate NPC1-mediated release of 
lysosome cargo 
In this chapter we propose that NPC1 plays an important functional role in 
regulating the concentrations of amines that are sequestered in lysosomes.  If 
this is the case, NPC1 should “sense” the amine accumulation and subsequently 
facilitate their clearance.  To evaluate this we examined the influence of 
exogenously supplied amines on the release of a membrane-impermeable cargo 
from lysosomes.  Previously, we had shown that the trafficking of dextran was 
severely impeded by NPC1 malfunction (Fig. 3.2).  Here we evaluate the 
influence of amines on the NPC1-mediated lysosomal egress of 10,000 MW 
dextran polymers.  We specifically localized [3H]-dextran to terminal endocytic 
compartments and evaluated its release into the cell culture medium as a 
function of time in both normal and NPC1-/- fibroblasts.  The amount of dextran 
released at the 24 h time point was found to be suitable for representing 
differences between normal and NP-C cells since this was the time point that 
showed the greatest difference between the two cell lines.  This was also true for 
NR-treated cells as shown in Figure 4.1, confirming the 24 h time point as 
suitable for determining secretion differences upon treatments.  Therefore, this 
single time point measurement was obtained for all subsequent experiments 
evaluating the influence of amines and other molecules on dextran release.  For 
comparison purposes, the amount of dextran released at the 24 h time point for 
the normal untreated NPC1+/+ fibroblasts was set to zero (Fig. 4.2).  Accordingly,  
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molecules having a stimulatory effect (resulting in the release of more dextran 
into the culture medium) will have positive deviations from the control.  
Alternatively, those treatments that inhibit dextran secretion relative to control 
cells will have negative deviations.   
 
Three lysosomotropic amines, NR, imidazole (IMDZ), and morpholine 
(MOR), had the unique ability to significantly stimulate the release of dextran 
from lysosomes of normal fibroblasts when administered at high concentrations 
(Fig. 4.2).  The reason for the administration of such high concentrations is due 
to the physicochemical properties of these molecules.  Although the molecules 
are all weakly basic, they have unfavorable logP values for membrane 
permeability (see Table I).  The concentrations used have been shown to 
sequester enough compound inside the lysosome to cause vacuolization [18].  
 
Since we were observing apparent stimulation of exocytosis of lysosomal 
contents, we investigated possible reasons for this increase upon amine 
exposure.  Considering the relatively short incubation time with these reagents (6 
hrs), up-regulation of NPC1 expression should not have had time to occur.  As 
expected, NPC1 levels similar to untreated cells were observed by Western blot 
analysis and densitometry (Fig. 4.3).  When non-vacuolizing amine 
concentrations were administered, the same degree of dextran release was not 
observed.  This was observed for low concentrations of NR and MOR (Fig. 4.4) 
and showed there was a concentration dependency for NPC1 involvement.   
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It is important to note that not every amine induced secretion.  For 
example, rhodamine 123 (R123), a weakly basic amine that is known to 
accumulate into mitochondria instead of lysosomes [19], did not induce or inhibit 
NPC1-mediated secretion (Fig. 4.5).  In addition to R123, we examined the effect 
of vacuole formation by the non-amine sucrose on 3H-dextran secretion and 
found no statistically significant change (Fig. 4.5). 
 
Somewhat paradoxically, it is well known that certain amphiphilic 
hydrophobic amines, instead of having a stimulatory role, cause lysosomal 
trafficking defects  [20].  Many of these compounds induce phenotypes similar to 
NP-C disease (hyperaccumulation of lipids), of which the best known is the 
weakly basic molecule U18666A (see Figure 4.14) [21; 22].  As anticipated, 
U18666A had a negative influence on NPC1-mediated dextran secretion in 
normal NPC1+/+ fibroblasts (Fig. 4.6).  It is likely that such amines elicit an 
inhibitory function unrelated to the molecule’s propensity for lysosomal 
sequestration (see Discussion).      
 
As expected, the release of dextran from NPC1-/- fibroblasts was less than 
that from normal untreated fibroblasts and similar to that from U18666A-treated 
normal NPC1+/+ fibroblasts (Fig. 4.7).  Importantly, the amines found to have 
stimulatory effects on NPC1-mediated secretion in normal cells had no significant 
impact on dextran release from NPC1-/- cells, which illustrates the specificity of 
the selected amines for NPC1 (Fig. 4.7).   
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These results demonstrate that select lysosomotropic amines can 
stimulate NPC1-mediated release of lysosomal cargo to the plasma membrane.  
There are at least two different pathways that lysosomal contents (i.e., dextran) 
could be trafficked to the cell surface: direct fusion with the plasma membrane 
and retrograde transport to other compartments such as late endosomes.  
Previous studies by Reddy and colleagues had shown that stimulation of 
lysosome secretion was mediated by elevations in cytosolic Ca2+ concentrations 
and the lysosomal protein synaptotagmin VII [23].  Furthermore, it has been 
shown that the accumulation of weak bases in lysosomes, such as ammonia and 
chloroquine, can elevate the lumenal pH [24; 25].  Lysosome pH increases have 
been linked to increases in cytosolic calcium levels [26].  To determine if the 
stimulation observed in 3H-dextran release studies was due to increased 
cytosolic Ca2+ concentrations upon amine exposure and subsequent fusion of 
lysosomes with the plasma membrane we examined if the amines tested caused 
elevations in cytosolic Ca2+ levels.  Interestingly, none of the stimulatory amines 
were able to significantly change cytosolic Ca2+ levels.  Morpholine treatments 
are shown as an example in Figure 4.9 for both cell lines.  
 
4.3.2. Certain lysosomotropic amines stimulate NPC1-mediated formation 
of the hybrid organelle compartment 
Ko et al. have suggested that NPC1 may facilitate the release of 
lysosomal cargo through a late endocytic hybrid organelle [3].  Therefore, we 
investigated if the stimulatory amines had an impact on the creation of a  
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lysosome/late endosome hybrid organelle.  To evaluate this fusion event, we 
utilized a concept for studying late endosome/lysosome fusion originally 
described by Jahraus et al. [13].  The approach involves the localization of 
specific tracers to each of these compartments and observation of their 
interactions.  In Jahraus’ method, terminal lysosomes were loaded with sucrose 
to form sucrosomes.  Next, late endosomes were specifically populated with 
endocytosed latex beads (~800 nm diameter) that were covalently coupled to 
invertase.  These beads have been shown not to reach terminal lysosomes due 
to an apparent size restriction in this transport step [13; 27].  The fusion of late 
endosomes with lysosomes was observed by the disappearance of sucrosomes 
as sucrose was enzymatically converted into fructose and glucose, which is 
subsequently transported out of the lysosome by membrane porters.  In our 
modified method, we utilized fluorescence resonance energy transfer (FRET) to 
quantitatively evaluate the fusion event in real time.  This was accomplished by 
endocytosing a biotinylated dextran (10,000 MW), covalently labeled with the 
FRET acceptor Alexa Fluor 647, into lysosomes using the same pulse-chase 
scheme described previously (Section 3.2.3.1).  Subsequently, a streptavidin-
conjugated latex bead (~800 nm diameter) tagged with the FRET donor Alexa 
Fluor 555 was added to cells to label late endosomes.  We evaluated the 
appearance of the FRET signal in untreated normal fibroblasts and cells treated 
with amines.  The lysosomotropic amines IMDZ and MOR stimulated retrograde 
fusion in normal cells (Fig. 4.10) and had no influence on NPC1-/- fibroblasts (Fig. 
4.11).  U18666A-treated normal fibroblasts had hybrid organelle formation rates  
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that were similar to those of NPC1-/- fibroblasts, which showed minimal hybrid 
organelle formation regardless of treatment (Fig. 4.12).  Furthermore, we 
investigated other cationic amphiphillic amines similar in structure to U18666A, 
imipramine, chlorpromazine, and amiodarone, to determine if inhibition of hybrid 
organelle formation was specific to U18666A.  We found that all of these 
molecules had a negative impact on hybrid organelle formation in normal 
fibroblasts after 3 h of exposure (Fig. 4.12).   The requirement of microtubules in 
this fusion step was shown by the decrease in FRET signal with nocodazole-
treated NPC1+/+ fibroblasts and was used as a control (Figs. 4.10 and Appendix 
I).  It was not possible to evaluate the effects of R123 or NR on hybrid organelle 
formation as was done in dextran release studies (Figs. 4.2 and 4.5), since their 
intrinsic fluorescence interfered with the spectral properties of Alexa Fluor 555. 
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4.4. Discussion 
Stimulation of direct lysosome exocytosis to the plasma membrane has 
been shown to occur in the presence of high cytosolic Ca2+ concentrations [28; 
29; 30; 31].  The cytosolic concentration increase needed for stimulation of 
lysosome exocytosis is approximately 1 µM above basal levels [28].  
Accumulation of weak bases in lysosomes has been shown to increase cytosolic 
levels of calcium [26]; however, the amine-stimulated release of lysosomal cargo 
described in this chapter does not appear to involve direct fusion with the plasma 
membrane since we do not observe elevations in free cytosolic Ca2+ upon 
administration of the weakly basic amine morpholine (Fig. 4.9).  The data 
presented here are consistent with a mechanism whereby amines accumulate 
into lysosomes and stimulate the NPC1-mediated formation of a hybrid organelle 
that results from fusion between late endosomes and lysosomes.  This statement 
is supported by several different experimental approaches that all show 
enhanced colocalization of lysosomal and late endosomal markers in the 
presence of amines, which was only observed in NPC1-competent cells (Figs. 
2.6, 2.8, and 4.10).   
 
Considering the fact that lysosomes are much denser than hybrid 
organelles, there must be steps involved in hybrid organelle fission that function 
to reduce membrane content.  This follows from the fact that if such reformation 
never occurred, all of the cell’s lysosomes would be “used up” in hybrid organelle 
formation.  In support of this, Mullock et al. have demonstrated  
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that dense core lysosomes are reformed after formation of late endosome-
lysosome hybrid organelles [32].  Furthermore, studies in live cells have shown 
small tubular structures budding off of late endosome/lysosome hybrid organelles 
[33].  Similarly, Ko et al. have visualized vesicles budding from NPC1-positive 
hybrid organelles [3].  It is likely that some of these vesicles would transport late 
endosomal membrane proteins back to their origin.  However, it is possible that 
some of the vesicles may fuse with the plasma membrane or with secretion 
competent organelles such as the Golgi apparatus.  We propose that it is these 
types of vesicles that traffic lysosomal cargo, such as undigested 
macromolecules (i.e., dextran), LDL-derived cholesterol, and protonated amines, 
to the plasma membrane.  A model of this hypothesis is described in Figure 4.13.   
 
The formation of hybrid organelles and their subsequent fission to reform 
lysosomes and late endosomes is a dynamic process [34].  Our data suggest 
that, at steady state, a relatively small fraction of lysosomes are fused with late 
endosomes, at any given time, under normal cell culture conditions.  This may or 
may not be relevant to in vivo situations.  It is possible that the rate of hybrid 
organelle formation (fusion) is small relative to the rate of reformation of 
lysosomes (fission) under normal conditions.  When cells in culture are exposed 
to select lysosomotropic amines at high concentrations, we observe nearly 100% 
colocalization of lysosomes with late endosomes in normal cells after 6 hrs of 
exposure (Chapter 2, Fig. 2.9).  One possible explanation is that the amines  
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stimulate NPC1-mediated fusion events, leading to the creation of hybrid 
organelles, yet have no influence on the subsequent fission events that are 
responsible for the disappearance of the hybrid organelle.  
 
  Nearly two decades ago, Liscum and Faust had shown that the weakly 
basic compound U18666A was able to impair the intracellular transport of LDL-
derived cholesterol from lysosomes [22]. This group has since identified a 
number of other, so-called, class II amphiphilic agents with related activity [35].   
The two most studied amines are U18666A and imipramine, and both are used 
to chemically induce a NP-C disease phenotype.  The exact mechanism of action 
for these agents remains poorly understood, but it is thought that they interfere 
with some aspect of lysosome to endoplasmic reticulum cholesterol transport.  
Thus, results showing that some amines had a stimulatory influence on NPC1-
mediated lysosome trafficking events would initially appear counterintuitive.  
However, it is important to consider what might differentiate weakly basic 
molecules that stimulate NPC1 from those that inhibit it.  We have previously 
evaluated how physicochemical properties of weakly basic molecules influence 
sequestration in lysosomes.  Specifically, we have found that pKa value, 
membrane permeability and charge delocalization are all important factors (Table 
I) [19; 36].  According to these parameters, we would predict NPC1 inhibitors 
(imipramine, chlorpromazine, amiodarone and U18666A) as well as the NPC1 
stimulators (neutral red, imidazole and morpholine) all have lysosomotropic 
properties, which is supported by the literature [18; 21; 37; 38; 39].  The 
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structures of each of the compounds are shown in Figure 4.14 and highlight 
distinct differences in the apparent amphiphilic nature of the molecules.  
Imipramine, chlorpromazine, amiodarone and U18666A all have clear separation 
between their basic ionizable tertiary amine and hydrophobic moiety.  
Morpholine, imidazole, and NR all possess an ionizable amine but do not have 
substantial hydrophobic character, which is apparent in their logP values (Table 
I).  Interestingly, imipramine and chlorpromazine have been shown to insert into 
lipid bilayers through orientations of their hydrophobic moieties [40; 41].  It could 
be that the amphiphilic nature of the inhibitory compounds allows them to insert 
and accumulate in membranes to a greater extent and consequently disrupt the 
activity of membrane proteins such as NPC1.  In support of this, the degree of 
amphiphilicity of a group of molecules has been shown to correlate well with their 
propensity to inhibit the activity of the membrane-bound transporter P-
glycoprotein [42]. 
 
When considering vesicle fusion, lipid asymmetry of the phospholipid 
membrane has been shown to be crucial for successful fusion events [43; 44].  
Ioannou suggests that NPC1 may function as a lipid flippase [45].  This function 
would allow late endosome-lysosome compartments to maintain the correct 
degree of lipid asymmetry.  This asymmetry, hypothetically, would in turn 
facilitate the correct membrane curvature required to drive vesicle fusion.  The 
work described in this chapter demonstrates that certain lysosomotropic amines 
are able to increase NPC1-mediated fusion of late endosomes and lysosomes. 
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We believe that this work is consistent with the previously proposed role for 
NPC1 in vesicle fusion.  The accumulation of amines in lysosomal compartments 
undoubtedly causes increases in both ionic strength and osmotic pressure in the 
organelle lumen.  These changes could potentially favorably influence membrane 
curvature to facilitate NPC1-mediated membrane fusion, although more work will 
be needed to address these mechanistic possibilities.   
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Connecting NP-C disease pathology with defects in lysosomal amine regulation 
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5.1. Introduction 
For many decades, NPC1 has been considered a cholesterol transporter 
due to the presence of a putative sterol sensing domain in the protein and the 
observed hyperaccumulation of cholesterol in lysosomes of NP-C disease cells.  
There is little doubt that NPC1 dysfunction affects cholesterol traffic; however, it 
is clear this is not NPC1’s only function.  Since NP-C disease research has 
revolved primarily around cholesterol, the numbers of exploratory studies that are 
designed to reveal other potential causes of NP-C disease pathology have been 
limited.  As a consequence, the rational development of therapeutic strategies for 
treating NP-C disease has, for the most part, failed due to the lack of 
understanding of NPC1’s function.  In this chapter we suggest a potential cause 
of the neurodegeneration observed in NP-C disease pathology that is unrelated 
to lysosomal cholesterol hyperaccumulation. 
 
In previous chapters, we provided evidence that suggests NPC1 plays an 
important functional role in regulating amine levels in lysosomes.  Could such a 
role be important in vivo?  First, vast arrays of endogenous small molecular 
weight amines exist in cells.  The most ubiquitous are polyamines (i.e., spermine, 
spermidine, putrescine, cadaverine), sphingoid bases, ammonia and other 
biogenic amines.  Interestingly, polyamines are found in every cell of our bodies.  
These molecules have importance with regards to cell proliferation, differentiation 
and motility as well as stabilizing DNA and RNA structure [1; 2; 3].  The 
concentrations of polyamines have been shown to be very high in cells, 
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sometimes reaching millimolar levels [4].  These levels are regulated by 
enzymes, which have dramatically short half-lives [5; 6], that synthesize and 
metabolize polyamines.  Considering this information, sequestration of 
polyamines in lysosomes without efficient NPC1-mediated release could cause 
imbalances in homeostatic levels.       
 
Although polyamine sequestration in lysosomes without release is 
plausible in NP-C disease, based on their physicochemical properties (highly 
positively charged at physiological pH), polyamines are not expected to 
accumulate by pH-partitioning in lysosomes.  However, a number of reports have 
suggested that polyamines and similar molecules can become extensively 
compartmentalized in lysosomes [7; 8; 9].  Furthermore, Brunk and coworkers 
have provided evidence concerning the intracellular distribution of polyamine 
metabolites in vivo [10; 11].  They have shown that a particular polyamine 
metabolite, 3-aminopropanal, localizes to lysosomes and can cause lysosome 
rupture, which results in apoptosis and cell death [10; 12].  Consistent with NP-C 
neurodegeneration, the toxic effects of 3-aminopropanal are greatly enhanced in 
neuronal cell lines although the reasons for this enhanced toxicity is currently 
unknown [12].       
 
Alterations in endogenous polyamine levels and/or their metabolizing 
enzymes have been reported to be associated with neurodegenerative disorders 
similar to NP-C disease [13; 14; 15] including Alzheimer’s disease.  The 
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contribution of these alterations to disease pathology is unclear at present.  
These similarities, however, give cause for investigation of polyamines in the 
pathology of NP-C disease.  In this chapter, we aim to investigate the 
contribution of polyamines to NP-C disease pathology.  Furthermore, we provide 
a physiologically relevant consequence of NPC1 dysfunction with regard to the 
regulation of polyamine metabolite accumulation in lysosomes.   
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5.2. Materials and methods 
5.2.1. Antibodies and reagents 
 Mouse monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) antibody was from Ambion (Austin, TX).  Goat polyclonal anti-
polyamine oxidase (PAO) was purchased through Santa Cruz Biotechnology 
(Santa Cruz, CA).  3-aminopropanal diethyl acetal was obtained from TCI 
America (Portland, OR).  Hyamine hydroxide was purchased through Fisher 
Scientific (St. Louis, MO).   Purpald (4-amino-3-hydrazino-5-mercapto-1,2,4-
triazole), propionaldehyde, 2, 4-dinitrophenol, p-nitrophenyl-N-acetyl-β-D-
glucosamidine (PNPG) and Dowex (50  x  2) cation exchange resin were 
obtained through Sigma-Aldrich (St. Louis, MO).  The Quick Cell Proliferation 
WST-1 assay was purchased from BioVision (Mountain View, CA).  All other 
reagents unless otherwise specified were purchased through Sigma-Aldrich. 
 
5.2.2. Cell culture and conditions 
Normal human fibroblasts (NPC1+/+) and Niemann-Pick Type C disease 
fibroblasts (NPC1–/–) were cultured as previously described (Chapters 2, Section 
2.2.2).  For all experiments, cells were used before passage 5 and plated 24 hrs 
prior to evaluations to allow for adherence.  Cells were transfected with NPC1 
siRNA as previously described (Chapters 2, Section 2.2.5).   
 
5.2.3. 3-Aminopropanal synthesis 
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 3-Aminopropanal (3-AP) was prepared, as previously described [16], from 
the hydrolysis of 3-aminopropanal diethyl acetal (145 mM) in 1.5 M HCl for 5 hrs 
at room temperature.  The resulting solution was then applied to a strong cation 
exchange resin (Dowex 50  x  2, H+ form) and eluted using a 0-3 M HCl gradient.  
Fractions were collected and aldehyde content was assayed by the method of 
Bachrach and Reches [17], and subsequently concentrated using a centrifugal 
evaporator at room temperature.  Aldehydes were spectrophotometrically 
measured at 530 nm using the aldehyde reactive probe Purpald and quantified 
using a standard curve constructed of propionaldehyde.  Detailed synthesis, 
purification and characterization of 3-AP is described in Appendix II. 
 
5.2.4. Cytotoxicity evaluations 
For cytotoxicity studies, fractions of 3-AP were neutralized to physiological 
pH using sodium hydroxide before use.  For experiments requiring NPC1 
depletion, NPC1+/+ cells (6 x 103 cells per well) were plated in 96-well plates and 
transiently transfected with NPC1 or scrambled siRNA.  At 72 hrs post 
transfection cells were exposed to various concentrations of 3-AP or ibuprofen 
(as a control).  Cell death was assessed using the WST-1 assay.  The WST-1 
assay is an equivalent of the MTT assay, except the formazan-like dye formed in 
the WST-1 assay is water soluble [18].  To obtain IC50 values, data points were 
curve fit to the 4-parameter Hill equation using the Dynamic Curve Fit function in 
SigmaPlot (v. 10).   
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5.2.5. Cytosol purification 
To determine the effects on lysosomal membrane integrity after exposure 
to 3-AP, cellular cytosol was purified as described previously by our laboratory 
[19].  Briefly, 3-AP was incubated with 50 x 106 cells at a previously determined 
IC-50 concentration.  Non-viable cells and debris were removed by washing with 
PBS (2X).  Viable cells were then harvested and homogenized using a dounce 
homogenizer.  Post nuclear supernatant (PNS) was prepared by centrifuging 
homogenized cells for 5 mins at 1,000 x g.  Cytosol was isolated by centrifuging 
the PNS of 3-AP exposed cells on a layered sucrose gradient (18% top, 86% 
bottom) in a Beckman Optima TLX centrifuge using a Beckman TLA100.4 fixed 
angle rotor at 150, 000 x g for 3 hours at 4oC.  Fractions of 300 µL were taken 
from the top and subsequently assayed for β-hexosaminidase activity as 
described below. 
 
5.2.6. β-hexosaminidase activity assay 
β-hexosaminidase activity was assayed as previously described by our 
laboratory using p-nitrophenyl-N-acetyl-β-D-glucosamidine (PNPG) as a 
substrate [20].  First, protein concentrations of purified cytosol fractions were 
determined by the method of Bradford.  3-AP treated and untreated cytosolic 
protein solutions were normalized to each other by dilution with 0.1 M citrate 
buffer (pH = 4.5) so that assay volumes were identical.  Next, aliquots of each 
cytosol fraction (0.1 mg total protein) were exposed to a solution containing 0.5 
mM PNPG in 0.1 M citrate buffer at pH 4.5.  This mixture was allowed to incubate 
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for 90 mins at 37oC to allow conversion of PNPG to p-nitrophenol (PNP).  After 
90 mins, the reaction was stopped with 0.8 mL of 0.1 M sodium bicarbonate 
buffer at pH 10.0.  Next, any precipitated proteins present were removed by 
centrifugation at 16,000 x g for 2 mins and the supernatant removed.  The 
absorbance at 405 nm of the supernatant was measured for PNP determination 
and compared to a standard curve constructed using 2, 4-dinitrophenol at the 
same absorbance.  The amount of PNP formed during the reaction was obtained 
and β-hexosaminidase activity is given as moles of PNP formed per mg of 
cytosolic protein. 
 
5.2.7. Ornithine decarboxylase activity assay 
 Ornithine decarboxylase (ODC) activity was assayed as previously 
described [21].  Briefly, 50 x 106 cells were harvested and resuspended in a 50 
mM Tris-HCl buffer and 0.1 mM EDTA at pH 7.4 (reaction buffer).  Cells were 
homogenized using 20 strokes in a glass dounce homogenizer at room 
temperature.  Protein levels were obtained using the method of Bradford to 
normalize protein concentrations between cell lines.  On the day of 
experimentation, 5 mM dithiothreitol and 0.1 mM pyridoxyl-5-phosphate (P5P) 
were added to 300 µL of reaction buffer.  Next, 100 µL of cell homogenate was 
added to the prepared reaction buffer.  To initiate the reaction, 10 µL of 14C-
ornithine was added to each protein solution.  Samples were allowed to incubate 
for 2 hrs at 37oC on an incubated shaker.  The reaction was stopped by 
precipitating proteins with trichloroacetic acid.  The detection of ODC activity was 
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accomplished by measuring the liberated radioactive carbon dioxide from 
ornithine.  To capture carbon dioxide, samples were incubated in glass pyrex test 
tubes with screw-on caps.  Inside the cap was a pre-cut square of Whatman filter 
paper that was soaked with 20 µL of hyamine hydroxide.  At the end of the 
reaction, this filter paper was removed and assayed using liquid scintillation 
counting.  The activity of ODC is expressed as moles of carbon dioxide formed 
per hour per mg of cellular protein.   
   
5.2.8. Western blot and densitometry analysis 
 Western blot and densitometry analysis was performed as previously 
described in Chapter 2, Section 2.2.3.  Primary antibodies were used at dilutions 
of 1:100 for PAO and 1:1000 for GAPDH.  Secondary HRP-conjugated 
antibodies were diluted 1:1000.    
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5.3. Results 
5.3.1. NPC1 deficient cells are more susceptible to 3-aminopropanal-
induced toxicity than normal cells 
Polyamines have been implicated in neurodegeneration through several 
possible pathways including metabolism of polyamines forming aldehydes [22; 
23; 24].  3-Aminopropanal is a polyamine metabolite that is formed endogenously 
from the metabolism of spermidine to putrescine by the enzyme polyamine 
oxidase (PAO).  This compound was selected since it has been shown to be 
specifically toxic to lysosomes and the numerous reports of its neurotoxic effects 
[23; 24].  Here, we specifically examined the comparative toxicity of 3-
aminopropanal (3-AP) in normal and NPC1-depleted fibroblasts. 
 
In cells with depleted NPC1 levels we reasoned that 3-AP should have 
more contact time with lysosomes and therefore an increased propensity to exert 
toxic effects relative to normal cells.  To test this hypothesis, 3-AP was 
synthesized and exposed to normal fibroblasts that were previously transfected 
with NPC1 siRNA and compared with cells transfected with a non-specific 
scrambled siRNA (Fig 5.1).  As expected, NPC1-depleted cells were more 
susceptible to 3-AP toxicity than cells expressing NPC1.  As a control, NPC1 
depletion and transfection conditions had no influence on the IC50 of a non-
lysosomotropic drug ibuprofen (Fig. 5.2).  
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5.3.2. Lysosomes of NPC1 deficient cells are more susceptible to 3-
aminopropanal induced rupture 
 Recent research has shown the main mechanism of 3-AP toxicity in cells 
is through the specific rupture of lysosomes [10].  From our previous cytotoxicity 
results, we expected that NPC1 deficient cells would allow 3-AP more residence 
time within lysosomes leading to more rupture. To assess if NPC1 dysfunction 
would permit greater lysosome instability in the presence of 3-AP, we assayed 
lysosomal enzyme activity in purified cytosol.  The presence of lysosomal 
enzymes in the cytosol is indicative of lysosome leakage or complete rupture 
[25].  To accomplish this, cytosol was purified after 3-AP administration and the 
presence of β-hexosaminidase, a well-known lysosome hydrolase, was assayed.  
We found that NPC1-/- lysosomes were more susceptible to rupture than 
lysosomes from normal cells since higher levels of β-hexosaminidase were 
observed (Fig. 5.3).   
 
5.3.3. Enzymes responsible for polyamine regulation and 3-aminopropanal 
synthesis are altered in NP-C disease cells 
Differential activities of enzymes that regulate polyamine concentrations in 
vivo have been shown in neurodegenerative disorders similar to NP-C disease 
[13; 15].  Here, we have evaluated the activity and/or expression of two enzymes 
responsible for the synthesis and metabolism of polyamines, ornithine 
decarboxylase and polyamine oxidase [2; 5]. 
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Ornithine decarboxylase (ODC) is the enzyme responsible for removing 
the c-terminus from the amino acid L-ornithine to form putrescine, which is the 
precursor of other polyamines such as spermine and spermidine (Fig. 5.4).  To 
investigate if ODC activity was altered in NP-C cells, we used a previously 
described assay [21].  Briefly, ODC enzyme activity was assayed by the 
formation of carbon dioxide that was removed from L-ornithine by ODC.  The c-
terminus of L-ornithine was radiolabeled such that the liberated CO2 gas was 
radioactive.  We found that in NPC1-/- cells, the activity of ODC was increased by 
~10% and was found to be statistically significant (p < 0.01) when compared to 
normal cells (Fig. 5.5). 
 
Polyamine oxidase (PAO) is the enzyme responsible for the generation of 3-
aminopropanal (3-AP) in cells (see Figure 5.6) [24].  Thus, we decided to 
comparatively examine PAO expression levels in NPC1-/- versus NPC1+/+ cells 
and found it to be significantly elevated in the diseased cell line (Fig. 5.7).  
Densitometry performed on PAO Western blot bands showed that expression 
was increased by approximately 300% in NPC1-/- cells when compared to normal 
cells.  Attempts at determining activity of this enzyme by monitoring the amount 
of polyamine substrate converted to aldehyde were unsuccessful using known 
methods for aldehyde detection.   
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5.4. Discussion 
 
 
In the work presented in this chapter we have focused on polyamines.  
The precise biological function of polyamines is controversial.  It is known, 
however, that changes in their levels and/or their biosynthetic enzymes have 
been associated with neurodegenerative-type disorders [13].  Specifically, 
polyamine levels have been shown to be significantly altered in Alzheimer’s 
disease [15].   
 
Progressive neurodegeneration is the ultimate cause of death in NP-C 
patients, yet it remains unknown why alterations in lipid homeostasis would lead 
to such profound neurological deterioration [26].  Alleviation of cholesterol 
accumulation in late endocytic compartments using pharmacological agents as 
well as genetic approaches do little to slow the onset of neurodegeneration in 
murine and feline disease models [27; 28].  Likewise, alleviation of neuronal 
ganglioside storage had no significant impact on disease progression [29].  Due 
to these setbacks in NP-C therapy, new avenues for disease treatment must be 
investigated.  
 
Wood et al. proposed, in a recent report, the theory of “aldehyde loading” 
as a possible mechanism for neurodegeneration.  In this report, they state that 
similar to oxidative stress, reactive aldehydes can cause modification of proteins 
and the decrease longevity of neuronal cells [24].  To establish this concept 
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the authors used a rat model (trimethyltin or TMT) that was previously reported to 
have alterations in polyamine synthesis/levels.  In this model, increased levels of 
polyamines were confirmed as well as increased levels of the reactive aldehyde 
3-AP.  Interestingly, the authors went on to alleviate the build-up of 3-AP in rats 
by neutralizing it with reactive hydroxylamine-containing compounds.  These 
aldehyde scavengers were able to increase the lifespan of TMT rats.  Unlike the 
hydroxylamine compounds, ascorbic acid, an anti-oxidant, did nothing to improve 
the lifespan of TMT rats.  These results suggest that aldehyde-containing 
molecules like 3-AP may be playing a major role in neurodegeneration and  that 
oxidative stress (from hydrogen peroxide) was a minimal contributor. 
 
In support of 3-AP sequestration contributing to NP-C disease through 
lysosome toxicity, studies using the anticancer agent tamoxifen have led to 
increases in the lifespan of an NP-C murine model [30].  Tamoxifen is a weakly 
basic molecule that has been shown to significantly elevate lysosome pH [31].  If 
the pH gradient is disrupted between lysosomes and cytosol, then it is expected 
that 3-AP would not significantly accumulate in lysosomes.  Thus, we would 
expect less 3-AP induced lysosome toxicity and more cell survival (see Figure 
5.1).    
 
Similar to the rat TMT model, our studies using NPC1-/- cells found that 
enzymes necessary for synthesizing and metabolizing polyamines are 
differentially expressed and/or overactive (Fig. 5.5 and 5.7).  Interestingly, 
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enhanced ODC activity is a common response to various pathological stimuli in 
the brain, including chemical or metabolic stress [14].  Although our observations 
concerning ODC activity in NPC1-/- cells are interesting, they do not provide 
sufficient evidence that 3-AP levels are increased.  Further evaluations 
concerning polyamine levels and reactive aldehyde species in NP-C tissues and 
cells are needed to be more conclusive.   
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Appendix I 
 
 
Development of a method for the quantitative determination of 
retrograde lysosome traffic to late endosomes 
 
 
 
 
 
 
The following is an adaptation of the recently submitted manuscript entitled:   
A fluorescence resonance energy transfer-based approach for determining 
retrograde lysosome traffic to late endosomes 
Kaufmann, A.M., Goldman, S.D., Krise, J.P. 
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A1.0.  Summary 
 
Traditionally, lysosomes have been considered to be a terminal endocytic 
compartment.  Recent studies, however, suggest that lysosomes are quite 
dynamic being able to fuse with other late endocytic compartments as well as 
with the plasma membrane.  Here we describe a quantitative fluorescence 
energy transfer (FRET)-based method for assessing rates of retrograde fusion 
between terminal lysosomes and late endosomes in living cells.  Late 
endosomes were specifically labeled with 800 nm latex beads that were 
conjugated with streptavidin and Alexa Fluor 555 (FRET donor).  Terminal 
lysosomes were specifically labeled with 10,000 MW dextran polymers 
conjugated with biotin and Alexa Fluor 647 (FRET acceptor).  Following late 
endosome-lysosome fusion, the strong binding affinity between streptavidin and 
biotin bring the FRET pair donor and acceptor molecules in close proximity, thus 
facilitating the appearance of a FRET signal. Since apparent size restrictions in 
the endocytic pathway do not permit endocytosed latex beads from reaching 
terminal lysosomes in an anterograde fashion, the appearance of the FRET 
signal is consistent with retrograde transport of lysosomal cargo back to late 
endosomes.  The applicability of this assay is demonstrated using human skin 
fibroblasts. 
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A1.1.  Introduction 
 
Lysosomes have long been considered as the terminal compartment for 
fluid phase endocytosis [1].  Recent findings, however, have shown that 
lysosomes are able to fuse with pre-lysosomal compartments in a retrograde 
fashion to result in the formation of so-called hybrid organelles [2; 3].  The 
precise function of such hybrid organelles in cells is not completely understood 
although Griffiths [4] has proposed a functional role for hybrid organelle 
formation.  It was hypothesized that lysosomes are not terminal degradative 
compartments for endocytosed materials, but are storage depots for active 
enzymes.  If needed, lysosomes can traffic enzymes in a retrograde fashion back 
to late endosomes, ultimately forming the primary endocytic site for degradation, 
the hybrid organelle.   Although novel, it still remains unclear the exact molecular 
stimuli that trigger this interaction to take place. 
 
Jahraus and coworkers [2] were the first to develop a cell-based method 
that clearly demonstrated the retrograde fusion of terminal lysosomes with pre-
lysosomal compartments.  Their method utilizes a pulse-chase technique 
specifically localizing sucrose to terminal lysosomes.  Since sucrose is not a 
substrate for lysosomal nutrient transporters, it can accumulate to an extent that 
induces the vacuolization of lysosomes.  Such vacuoles are referred to as 
sucrosomes and are clearly visible using conventional light microscopy.  
Subsequently, cells are incubated with 800 nm latex beads conjugated to the 
enzyme invertase (sucrase).  Latex beads of this size are unique in that they are 
 186 
endocytosed by cells but, by virtue of their size, fail to progress beyond late 
endosomes to lysosomes [5].  When in the presence of invertase, sucrose is 
converted into glucose and fructose, both of which are rapidly transported across 
lysosomal membranes by specific transporter proteins [6].  Transport of these 
molecules dissipates the lysosome-cytosol sucrose concentration gradient and 
results in the shrinking of the sucrosome.  Thus, a reduction in sucrosome size is 
indicative of retrograde fusion of lysosomes with late endosomes.  Despite its 
usefulness in demonstrating retrograde lysosome-late endosome fusion, this 
method cannot be readily employed to examine rates of hybrid organelle 
formation. 
 
In this work we examined if the concept developed by Jahraus and 
colleagues [2] could be redesigned to provide a quantitative measure of 
retrograde lysosome-late endosome fusion.  To accomplish this we investigated 
the suitability of a fluorescence resonance energy transfer (FRET)-based readout 
for assessing the extent of these fusion events in living cells..  Specifically, we 
localized 10,000 MW dextran polymers to lysosomes, instead of sucrose, using 
previously described pulse-chase protocols [7].  The dextran polymer was 
coupled with biotin and fluorescently labeled with Alexa Fluor 647 (FRET 
acceptor).  Next, we localized latex beads into late endosomes as previously 
described [2].  The beads were of the same diameter previously used by Jahraus 
et. al. but were conjugated with streptavidin, instead of invertase, and 
fluorescently labeled with Alexa Fluor 555 (FRET donor).  If lysosome and late 
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endosome contents mix, the strong binding affinity of streptavidin for biotin 
should result in the dextran binding to the latex bead.  As a result the FRET 
fluorophores will be in close proximity to each other and result in the appearance 
of FRET signal, which is calculated using the fluorescence intensities of the 
donor and acceptor fluorophores [8; 9].  By monitoring the appearance of new  a 
FRET signal over time, we obtain a quantitative read-out describing the extent of 
retrograde traffic originating from the lysosome.  To assess the specificity of the 
assay for retrograde lysosome traffic and the appearance of FRET signal, a 
series of controls were also performed. 
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A1.2.  Materials and methods 
A1.2.1. Cell culture 
 Normal human fibroblasts were purchased from the ATCC and cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% 
penicillin/streptomycin and 5% bovine calf serum.  Cells were cultured in Corning 
cell culture flasks at 37oC in a 5% CO2, humidified atmosphere until monolayers 
were 80% confluent at which time they were subcultured or seeded for 
experimentation.  All experiments were performed with cells before passage 5.  
For FRET experiments, a TC-MI temperature controlled, humidified chamber 
from Bioscience Tools (San Diego, CA) was used for the duration of the 
experiment. 
 
A1.2.2. Lysosome isolation 
Lysosomes were isolated using the methods of Duvvuri et al. [7] with 
modifications to permit isolations of adherent cells as described in Chapter 2, 
Section 2.2.8.   
 
A1.2.3. Western blot analysis 
Western blot analysis was performed using procedures described 
previously in Chapter 2, Section 2.2.3 [7].  Primary antibodies were LAMP1 
(1:500), CI-MPR (1:50), EEA1 (1:250), and Golgin-84 (1:250).  Secondary HRP-
conjugated antibodies were diluted 1:1000.  Bands were visualized by adding 
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enhanced chemiluminescence reagents and imaged using Kodak Biomax MR 
Scientific Imaging Film.   
 
A1.2.4. Fluorescence microscopy 
Images were acquired by a Nikon Eclipse 80i microscope equipped for 
epifluorescence using a Hamamatsu Orca ER camera and MetaMorph software 
(v. 7.0).  Filter sets specific for Cy5 and rhodamine (Cy3, Chroma) were used to 
detect Alexa Fluor 647 and 555 in cells, respectively.  Microscope settings were 
kept identical for the duration of experiments.  Merged images were constructed 
using the Image Overlay function with original brightness/contrast settings for 
each image.  Immunofluorescence was accomplished as described previously 
(Chapter 2, Section 2.2.6).  Antibodies specific to MPR and LAMP-1 were diluted 
1:100 and 1:500 respectively.  
 
A1.2.5. Fluorescent FRET tracer construction 
The fusion between late endosomes and lysosomes was evaluated in 
fibroblasts using a method described by Jahrus et al. [2] with modifications to 
allow for quantitative assessments based on fluorescence resonance energy 
transfer (FRET) of late endosome/lysosome contents upon fusion.  To construct 
the FRET donor and acceptor, standard labeling strategies were employed as 
described below:   
 
A1.2.5.1. Lysosome tracer 
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 Biotinylated-dextran-amine (10,000 MW, BDA-10000) was 
fluorescently labeled with the amine-reactive succinimidyl ester derivative 
of Alexa Fluor 647 per Invitrogen’s instructions.  According to the 
manufacturer, there are two lysine residues per molecule of dextran for 
Alexa Fluor 647 conjugation.  First, the Alexa Fluor 647 was reconstituted 
in dry DMSO to a concentration of 10 mg/mL.  BDA-10000 was 
reconstituted to 50 mg/mL in 0.1 M sodium bicarbonate buffer (pH 9.0, 
Buffer A) of which a 100 µL aliquot was added to 75 µL of Buffer A and 25 
µL of 10 mg/mL Alexa Fluor 647 stock solution.  The reaction was carried 
out at room temperature for 2 hrs and was quenched with 1 M Tris to a 
final concentration of 90 mM.  The resulting solution was desalted five 
times using protein desalting columns from Thermo Scientific (Rockford, 
IL) to remove unconjugated Alexa Fluor 647 and remaining Tris. 
 
A1.2.5.2. Late endosome tracer 
For the late endosome tracer, carboxylate-modified mono-disperse 
polystyrene beads (2.5% solids, 1.08 x 1011 beads/ml, 0.792 ± 0.037 µm) 
were used.  First, the beads were activated using N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide (EDAC) to make the 
carboxylate moiety an amine-reactive center.  To accomplish this, 4 mL of 
the polystyrene beads were washed 3 times with 0.1 M MES buffer (pH 
6.0, Buffer B) by centrifuging the beads at 5,000 x g for 20 mins and 
resuspending with Buffer B.  Immediately after the final wash, the beads 
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were resuspended to a 2% solids mixture in Buffer B and 2 mL of freshly 
prepared 50 mg/mL EDAC was added drop-wise to the suspension.  The 
EDAC was allowed to activate the carboxylate groups for 15 mins at room 
temperature followed by three washes with 0.1 M PBS (pH 7.4, Buffer C).  
Activated beads were then resuspended in 5 mL of Buffer C for 
subsequent streptavidin conjugation by means of their surface exposed 
lysine residues.  Lyophilized streptavidin, from Invitrogen, was 
reconstituted in Buffer C at a concentration of 1 mg/mL of which 5 mL was 
added to the activated beads solution for 3 hrs at room temperature.  
Unconjugated streptavidin was removed by extensive washing with PBS.  
The beads were centrifuged and stored at 4oC in a solution of Buffer C 
containing 0.1% glycine to mask any unreacted sites.  Fluorescence 
labeling of the streptavidin conjugated beads was carried out using the 
succinimidyl ester derivative of Alexa Fluor 555 per Invitrogen’s 
instructions.  First, 1 mL of streptavidin-conjugated beads was washed 2 
times with Buffer A to remove the glycine storage buffer and resuspended 
back to 1 mL.  An Alexa Fluor 555 aliquot of 10 µL of a 10 mg/mL solution 
was added to the freshly washed beads.  Labeling was performed at room 
temperature for 2 hrs and subsequently quenched with Tris.  Unreacted 
Alexa Fluor 555 was removed with extensive washing with PBS.  
Subsequent dialysis was performed against PBS using a dialysis cassette 
with a 3.5 kDa cutoff.  Beads were centrifuged once more, resuspended in 
PBS, and stored at 4oC until needed. 
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A1.2.6. Tracer localization and drug treatments 
To evaluate the fusion of late endosomes and lysosomes, cells were 
seeded in 8-well culture chambers at 75 x 104 cells per well.  Cells were 
incubated for 2 hrs with 2.5 mg/mL Alexa Fluor 647 biotinylated dextran in 
complete phenol red-free DMEM medium, washed once with PBS, and given 
chase in complete medium for 20 hrs to ensure localization into the lysosome.  
After 20 hrs post-chase, cells were exposed to 1.28 x 107 beads/mL of Alexa 
Fluor 555 streptavidin-conjugated latex beads for 2 hrs and chased for 1 h to 
label the late endosomal compartment.  FRET measurements were started 
immediately after the localization of the latex bead to the late endosome 
compartment.  Nocodazole (50 µM), a microtubule depolymerizing agent, was 
added to respective wells 1 h after the start of FRET measurements.  For all 
other treatments shown in Chapter 4, Section 4.3.2, administration was started 
immediately after the late endosome tracer chase.      
 
A1.2.7. Fluorescence intensity measurements and analysis 
Monolayers were analyzed using a Photon Technologies International 
(Birmingham, NJ) Ratiomaster microscope-mounted spectrofluorometer.  This 
setup employed a scanning monochromator for precise excitation wavelengths 
(lamp slit widths set at 2.5 nm).  Detection of fluorescence signals was 
accomplished using a PMT detector attached to one of the microscope camera 
ports.  Dichroic mirrors and emission filters were employed to segregate specific 
emissions of the two FRET fluorophores (see schematic of experimental setup in  
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Figure A1.1).  For each time-point, three measurements were made, 
corresponding to the Alexa Fluor 555 donor excitation/emission (ex: 550 nm, em: 
610/40 nm, dichroic: 565 nm longpass), donor excitation/acceptor emission 
(FRET, ex: 550 nm, em: 710/60 nm, dichroic: 565 nm longpass), and Alexa Fluor 
647 acceptor excitation/emission (ex: 650 nm, em: 670/40 nm, dichroic: 660 
longpass).  For fluorophore spectra see Figure A1.2.  All dichroic and emission 
filters were from Chroma (Rockingham, VT).  
  
There are many contributing factors that can result in FRET signal artifacts 
in living cells including cellular autofluorescence [10; 11], spectral cross talk, and 
differential concentrations of the donor and acceptor present [9; 11; 12].  To 
account for autofluorescence from our experimental conditions, we measured 
fluorescence emission intensities of cells without probes, at wavelength intervals 
corresponding to each of the probes, in the presence of phenol red-free DMEM 
medium containing fetal bovine serum.  Although no significant emission peaks 
were observed around wavelengths used to measure Alexa Fluor 555 and 647, 
there was significant background that contributed to the probes apparent signal  
strength (Fig. A1.3).  These scans, without probes, were subsequently subtracted 
from experimental data before calculating FRET signal. 
 
For fluorescence microscopy evaluations, the donor and acceptor probes 
did not visually bleed through (detection of donor fluorescence with the acceptor 
emission filter or detection of acceptor fluorescence with the donor emission filter)  
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their counterparts’ filter sets (Fig. A1.4).  However, to compensate for both 
spectral cross talk of the FRET probes and the propensity of cell populations to 
endocytose differential amounts of the probes (although both sets of cells were 
similar in the uptake of FRET probes, see Figure A1.5A and B), we applied a 
widely used equation for the normalization of donor and acceptor intensities for 
FRET calculation (Eq. 1) [9; 12; 13; 14].  Correction factors α and β were 
determined to be 0.011 and 0.799, respectively for our experimental setup. 
      
Initial calculated FRET ratio values for each experiment were then 
normalized to zero and the appearance of new FRET ratio signal was evaluated 
over time.  Each acquisition was no longer than 10 s. 
 
 
 
 
 
 
 
 
 
Eqn 1.  
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A1.3.  Results 
A1.3.1. Synthesis and characterization of FRET probes  
Based on previously described methods for specifically localizing probes 
to lysosomes and late endosomes [2], modified organelle probes were 
constructed and conjugated with either streptavidin or biotin and a fluorophore 
that could be utilized for FRET studies.  For lysosomes, we utilized a 
commercially available 10,000 MW dextran polymer that was conjugated with 
both biotin and lysine groups.  For late endosomes, we conjugated carboxylate-
modified latex beads, of the same diameter (0.792 µm) used by Jahraus et al., 
with streptavidin.  Fluorescence labeling of the probes was accomplished by 
using amine-reactive succinimidyl ester derivatives of the known FRET pair 
Alexa Fluor 555 (AF555, donor) and 647 (AF647, acceptor) against lysine 
residues present on streptavidin or dextran, respectively.  To confirm specific 
binding of the biotinylated-dextran with streptavidin-coated beads in vitro, both 
probes were mixed, extensively washed, and imaged.  The addition of 
biotinylated-dextran to a solution of streptavidin beads resulted in the 
appearance of dextran on the perimeter of the beads (FIG A1.6).  Binding of the 
probes allows the FRET fluorophores to come in close proximity to each other, 
which is required for efficient FRET to occur [8].  Alexa Fluor 488 dextran, without 
biotin, was used as a negative control and did not bind to the streptavidin beads 
under the same conditions (Fig. A1.6).   
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Hoppe et al. has reported that pH-dependent fluorescence intensity 
fluctuations of FRET fluorophores can result in decreased FRET efficiency 
between donor and acceptor molecules [13].  To be certain that our FRET probes 
were suitable for studies in which environmental pH could be manipulated, 
whether from endogenous factors or exogenously supplied agents, we 
characterized fluorescence intensities over a broad pH range.  We found that 
fluorescence intensities remained constant for each probe and did not fluctuate 
significantly at pH values relevant to the endocytic pathway (Fig. A1.7). 
 
A1.3.2. Intracellular localization of the FRET probes  
To test the suitability of our pulse-chase protocols, we examined the 
intracellular localization of both FRET probes in normal human fibroblasts.  To 
accomplish this, subcellular organelle isolations and immunofluorescence 
microscopy were performed after the probes were endocytosed as described in 
Materials and Methods.  For immunofluorescence, cells were fixed and probed 
with antibodies specific to the lysosome associated membrane protein-1 (LAMP-
1) for lysosomes and the cation-independent mannose-6-phosphate receptor (CI-
MPR) for late endosomes.  The majority of the biotinylated-dextran was found in 
LAMP-1 positive, CI-MPR negative organelles (Fig A1.8A) indicative of the 
lysosome [15].  For lysosome isolations, a super-paramagnetic iron dextran was 
localized to lysosomes using the same incubation conditions as the biotinylated-
dextran.  Lysosomes were then purified using a magnetic chromatography 
approach developed in our laboratory [7].  Western blot analysis revealed the  
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presence of CI-MPR in the post nuclear supernatant (PNS) but not in the isolated 
fraction (Fig. A1.8B).  Furthermore, there was no significant localization into 
either the Golgi apparatus (Golgin-84) or early endosomes (EEA1), suggesting 
the biotinylated-dextran is almost completely present in lysosomes when using 
optimized pulse-chase conditions (Fig. A1.8C).  Immunofluorescence of cells 
incubated with streptavidin beads shows localization within CI-MPR positive 
organelles, indicating that the beads were predominantly in late endosomes (Fig. 
A1.8D). 
 
A1.3.3. Interactions of FRET probes occur in vivo 
Previously we had shown that our FRET probes could bind in vitro (Fig. 
A1.6).  Considering the lumenal composition of late endosomes and lysosomes 
is much more complex than PBS, we evaluated if the FRET probes could interact 
and be colocalized to a significant degree in living cells.  To accomplish this, 
dextran was endocytosed as before and cells were visualized using fluorescence 
microscopy at the end of the streptavidin bead chase (0 h) and 24 hrs post-
chase.  Initially, the two probes were visualized in separate compartments.  
However, at 24 hrs post-chase, dextran signal was observed in bead containing 
compartments suggesting a significant portion of lysosomal dextran was bound 
to the streptavidin bead (Fig. A1.9).   
 
In addition to colocalization experiments, we also observed the interaction 
of lysosomes with late endosomes using time-lapse video microscopy.  We found 
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that dextran laden lysosomes could interact with bead containing late endosomes 
through different mechanisms: transient and complete organelle fusion (Figures 
A1.10 and A1.11).  The transient interactions of lysosomes and late endosomes 
were confirmed by measuring the fluorescence intensity of donor beads before 
and after acceptor dextran was deposited.  As expected, the trafficking of 
acceptor dextran slightly quenched the emission intensity of the donor latex 
beads (Fig. A1.11B). 
 
A1.3.4. Detection of a FRET signal is dependent on probe binding affinity 
For efficient FRET to occur, donor and acceptor fluorophores are required 
to be in close proximity to each other (see Figure A1.12) [8].  Streptavidin and 
biotin facilitate this requirement for FRET when bound together and have been 
used in previous FRET-based studies [16].  If the appearance of a FRET signal 
over time in our assay was dependent on probe affinity, then latex bead 
conjugation to a protein with less affinity for biotin should result in a decreased 
FRET signal.  To evaluate if streptavidin was needed for assay sensitivity, we 
constructed new beads by conjugating bovine serum albumin (BSA) to latex 
beads and fluorescently tagging it with AF555.  Next, we evaluated each set of 
latex beads, streptavidin and BSA, in living cells previously incubated with 
biotinylated-dextran.  To use Equation 1, we made 3 separate fluorescence 
intensity measurements: Alexa Fluor 555 beads, Alexa Fluor 647 dextran and the 
FRET measurement as described in Materials and Methods.   
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We observed that beads coated with BSA had higher fluorescence 
emission intensity when excited at the donor excitation of 550 nm than that of the 
streptavidin coated beads (Fig. A1.13A).  In the absence of biotinylated-dextran, 
BSA-coated beads had a lower fluorescence signal than streptavidin beads (Fig. 
A1.14).  More importantly, the FRET measurement showed streptavidin coated 
beads had much higher signals when compared to the BSA control beads (Fig. 
A1.13B).  This decrease occurs because the donor emission intensity is 
efficiently quenched by the presence of an acceptor fluorophore.  This does not 
occur with BSA-conjugated beads.  Measurements of the total biotinylated-
dextran fluorescence were similar (Fig. A1.13C).  This verified that the increased 
signal for the streptavidin beads in the FRET measurement was not due to 
differential biotin dextran endocytosis but was from probe interactions.  When 
monitored for a period of 3 hrs, no FRET signal appeared when using BSA-
conjugated latex beads.  However, experiments with streptavidin show that a 
significant amount of FRET signal appears over time due to its ability to strongly 
bind biotin (Fig. A1.15).  These results suggest that strong binding between the 
probes is needed for efficient FRET permitting the sensitive detection of 
retrograde trafficking from lysosomes in living cells. 
 
A1.3.5. Retrograde Transport of Lysosome Cargo to Late Endosomes is 
Microtubule Dependent 
The movements of lysosomes and late endosomes have been shown to 
be microtubule dependent [17].  The addition of a reagent that destabilizes  
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microtubules and thus inhibits the contact between lysosomes and late 
endosomes, should diminish retrograde traffic and thus the FRET signal over 
time.  To test this, the microtubule-destabilizing agent nocodazole (NOC) was 
incubated with cells.  First, lysosomes and late endosomes were allowed to 
interact for 1 h, at which point cells were either treated with 50 µM NOC or left 
untreated.  By not pre-treating cells with NOC prior to FRET measurements, we 
create the same initial conditions with respect to probe uptake since NOC would 
affect microtubule dependent endocytosis of the latex beads.  Furthermore, 
allowing lysosomes and late endosomes to interact for 1 h allowed us to evaluate 
the post-administration effects of NOC in real time.  After NOC treatment, the 
appearance of new FRET signal was minimal compared to that of normal 
untreated cells (Fig. A1.16).  This indicated NOC destabilization of the 
microtubule network impacted organelle interactions and ultimately the ability of 
biotinylated-dextran to be delivered to the late endosome via the retrograde 
lysosome pathway. 
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A1.4. Discussion 
To date, there have been several different approaches developed to 
investigate the interactions of lysosomes and late endosomes [2; 18; 19].  
Mullock et al. described a cell-free content mixing assay based on the mixing of 
purified late endosomes and lysosomes harvested from rat livers [19].  Briefly, 
organelle labeling was accomplished by endocytosing avidin-ASF for late 
endosomes, 125I-biotinylated-IgA for lysosomes and subsequently purified.  Each 
of the purified fractions were separately reconstituted in cytosol containing an 
ATP-regenerating system and added together.  Evidence of late endosome-
lysosome fusion was determined by immunoprecipitation of avidin-ASF which 
bound to 125I-biotinylated-IgA if the two organelles were fused.  Use of this assay 
has identified many components, such as SNARE, SNAP and Rab GTPase 
proteins, which are necessary for fusion of lysosomes with late endosomes [20; 
21].  Although highly elegant and informative, such an assay requires lengthy 
and complex organelle isolation procedures from animals and radioactive 
reagents.  Jahraus et al. described a cell-based method for observing retrograde 
lysosome fusion with late endosomes [2].  This method adequately described 
retrograde lysosome traffic; however, detection of this event was qualitatively 
accomplished with light microscopy.  This detection methodology would not be 
suitable for evaluating slight changes in the rates of retrograde traffic that could 
be useful in identifying the molecular mechanisms underlying this trafficking 
pathway.     
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In this chapter we describe a method for evaluating late endosome-
lysosome fusion that offers significant advancement over previous methods, 
specifically: 1) quantitative assessment of retrograde lysosome traffic, and 2) its 
utility for high throughput applications.  This approach should permit future 
studies to elucidate proteins and potential small molecular weight factors that 
influence this retrograde trafficking step.  Furthermore, it is likely that this assay 
could be used to study lysosomal storage disorders, as has been done in this 
dissertation with NP-C disease, to identify small molecular weight therapeutic 
agents that may appropriately modulate this trafficking event and be used in the 
treatment of such diseases. 
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Synthesis and characterization of the toxic polyamine metabolite 3-aminopropanal 
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A2.1.  Introduction 
 
 3-Aminopropanal (3-AP) is an endogenously synthesized amino-aldehyde 
that has been shown to localize to lysosomes by a pH-partitioning type 
mechanism [1].  The accumulation of 3-AP has been linked to the rupture of 
lysosomes in cell culture models [2; 3].  Furthermore, in vivo, 3-AP has been 
implicated as a potent neurotoxin responsible for neurodegeneration [1; 4; 5; 6; 
7; 8].  In this dissertation, we have implicated the NPC1 protein functioning as a 
regulator of amine concentrations in lysosomes.  Since 3-AP is an endogenous 
metabolite of polyamines, we propose that the NPC1 protein plays an important 
role in regulating concentrations of these molecules in lysosomes to avoid 
cellular toxicity.  Thus, 3-AP gives us an opportunity to evaluate a physiologically 
relevant amine in NPC1 deficient cells.  The synthesis and characterization of 3-
AP for use in cell-based evaluations is discussed in this appendix.   
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A2.2. Materials and methods 
A2.2.1. Reagents 
 3-aminopropanal diethyl acetal (3-APDA) was obtained from TCI America 
(Portland, OR).  Purpald (4-amino-3-hydrazino-5-mercapto-1,2,4-triazole), 
propionaldehyde, and Dowex (50  x  2) cation exchange resin (H+ form) were 
obtained through Sigma-Aldrich (St. Louis, MO).  All other reagents unless 
otherwise specified were purchased through Sigma-Aldrich. 
 
A2.2.2. 3-Aminopropanal synthesis 
 3-Aminopropanal (3-AP) was prepared, as previously described [8], from 
the hydrolysis of 3-APDA (see Figure A2.1 for mechanism).  3-APDA was 
supplied as a solution with a specific gravity of 0.91 g/L.   To accomplish 
hydrolysis of the acetal groups, 1.16 mmol 3-ADPA (0.188 mL of stock 3-APDA 
solution) was added to 5 mL of 1.5 M HCl for a final concentration of 145 mM 3-
ADPA at room temperature.  The reaction was carried out for 5 hrs at room 
temperature in a stirred flask. 
 
To separate amino-aldehydes, the reaction mixture was passed through a 
freshly prepared cation exchange column.  To prepare the column, Dowex (50 x 
2) a strong cation exchange resin was rinsed (3X) with water.  Washed resin was 
packed into a thin (1 x 30 cm) glass column with a stopcock and glass wool at 
the bottom.  Next, 50 mL of an aqueous wash solution (pH 4, titrated with HCl) 
was added to the resin.  Once the column was prepared, the reaction mixture  
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was added and the flow through was collected for later aldehyde analysis.  The 
column was eluted using a linear gradient of HCl (0-3 M) with a total volume of 
120 mL being used.  Fractions were collected every 10 mL and kept for aldehyde 
analysis (Fig. A2.2).  Fractions were then concentrated (Fig. A2.3) using a 
centrifugal evaporator at room temperature for 4 hrs prior to mass spectrometry 
or nuclear magnetic resonance (NMR).    
 
A2.2.3. Aldehyde determination 
Aldehyde content was assayed by the method of Bachrach and Reches 
[9], for each fraction collected.  First, the aldehyde reactive probe Purpald was 
prepared at 50 mg/ml (34 mM) in 2 N HCl.  Next, an aldehyde standard curve 
was constructed using propionaldehyde diluted in PBS (Fig. A2.4).  For sample 
analysis, 100 µL of each standard or unknown (prepared by 1:100 dilution in PBS 
from collected fraction) was added to a 96-well plate.  To start the reaction, 100 
µL of 34 mM Purpald solution was added to each well.  The reaction was shaken 
at room temperature for 20 mins before reading absorbance at 530 nm using a 
plate reader (Multiskan, Thermo Scientific).  By determining the presence of 
aldehydes formed during the reaction we calculated that 89% of the parent 
compound 3-APDA was converted to 3-AP.    
 
A2.2.4. Mass spectrometry 
 Mass spectrometry was performed on aldehyde containing fractions post-
concentration using an API-2000 ion spray MS/MS (Applied Biosystems).   
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Aldehyde containing solutions were injected directly into the mass spectrometer 
in positive ion mode with a Q1 (first quadrapole only) scan type.  Parameters 
were as follows:  curtain gas = 15, ion-spray voltage = 5500, temperature = 200, 
declustering potential = 20, focus potential = 400.  Mass peaks were observed 
from 50 – 500.    
 
A2.2.5. 1H-NMR characterization 
 NMR characterization was performed by the Molecular Structures Group 
(Nuclear Magnetic Resonance Laboratory) at the University of Kansas 
(Lawrence, KS).  Concentrated aldehyde-containing samples were reconstituted 
in D2O and submitted for routine proton 
1H-NMR analysis using an Avance AV-III 
spectrometer with a 500 MHz magnet.   
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A2.3. Results 
A2.3.1. Mass spectrometry 
 3-AP has been successfully synthesized by other labs [4; 8] using similar 
conditions; however, we needed to confirm the presence of 3-AP at the end of 
the reaction.  The purpose of using a mass spectrometer (MS) was to identify the 
masses of the products present upon completion of the reaction.  Simple 
injections were made into the MS of the retained fraction with the most aldehyde 
content present (concentrated fraction 5).  Although the results revealed other 
components in the fraction other than 3-AP, we were able to observe the 
presence of 3-AP (Fig. A2.5).  The molecular weight of 3-AP is 73.1.  These 
injections told us only that 3-AP was present in this fraction and were not meant 
to be quantitative.  Thus, the sizes of any contaminating peaks do not translate to 
concentrations relative to the 3-AP peak.  
 
A2.3.2. Nuclear Magnetic Resonance 
 To alleviate any concerns about the presence of other compounds in the 
reaction mixture other than 3-AP observed by MS analysis, we evaluated 
concentrated aldehyde-containing fractions (fraction 5 from Figure A2.3 is shown 
in Figure A2.6) by 1H-NMR.  We observed the predicted sets of peaks for 3-AP, 
in addition to peaks for water.  Peaks representing the different hydrogen atoms 
of 3-AP are shown in Fig. A2.6.  Note the presence of the upfield aldehyde peak 
at approximately 9.7 ppm.  Significant amounts of contaminating peaks were not 
observed suggesting we had obtained a pure fraction of 3-AP from the ion 
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exchange column.  This correlates well with our calculation of 89% conversion of 
3-APDA to 3-AP.  
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